WWW - Atsdr.cdc - Gov/csem/ Downloadable PDF

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM)

Chromium Toxicity
Course: WB 1466
Original Date: December 18, 2008
Expiration Date: December 18, 2011
Table of Contents
How to Use This Course ...................................................................................................3

Initial Check...................................................................................................................5
What Is Chromium? ........................................................................................................9
Where Is Chromium Found? ........................................................................................... 13
What Are the Routes of Exposure for Chromium?............................................................... 17
Who Is at Risk of Exposure to Chromium? ........................................................................ 20
What are the Standards and Regulations for Chromium Exposure? ....................................... 22
What Is the Biologic Fate of Chromium in the Body? .......................................................... 26
What Are the Physiologic Effects of Chromium Exposure?.................................................... 29
Clinical Assessment - History, Signs and Symptoms ........................................................... 39
Clinical Assessment - Laboratory Tests............................................................................. 43
How Should Patients Exposed to Chromium Be Treated and Managed? ................................. 47
What Instructions Should Be Given to Patients Exposed to Chromium? ................................. 51
Sources of Additional Information.................................................................................... 54
Posttest ....................................................................................................................... 58
Literature Cited ............................................................................................................ 62
Key Concepts • The toxicity of chromium compounds depends on the oxidation state of
the metal.
• Occupational exposure to chromium(VI) compounds has been
associated with increased incidence of lung cancer.
• Chromium(III) is an essential nutrient that can be toxic in large doses.
About This and This educational case study document is one in a series of self-instructional
Other Case publications designed to increase the primary care provider’s knowledge of
Studies in hazardous substances in the environment and to promote the adoption of
Environmental medical practices that aid in the evaluation and care of potentially exposed
Medicine patients. The complete series of Case Studies in Environmental Medicine is
located on the ATSDR Web site at www.atsdr.cdc.gov/csem/. In addition, the
downloadable PDF version of this educational series and other environmental
medicine materials provides content in an electronic, printable format,
especially for those who may lack adequate Internet service.
How to Apply See Internet address www2.cdc.gov/atsdrce/ for more information about
for and Receive continuing medical education credits, continuing nursing education credits,
Continuing and other continuing education units.
Education
Credit
Page 1 of 67
Agency for Toxic Substances and Disease Registry Chromium Toxicity
Acknowledgments We gratefully acknowledge the work that the medical writers, editors, and
reviewers have provided to produce this educational resource. Listed below
are those who have contributed to development of this version of the Case
Study in Environmental Medicine.
Please Note: Each content expert for this case study has indicated that
there is no conflict of interest to disclose that would bias the case study
content.
CDC/ATSDR Author(s): Dianyi Yu, M.D.
CDC/ATSDR Planners: Charlton Coles, Ph.D.; John Doyle, MPA; Bruce

Fowler, PhD.; Kimberly Gehle, MD; Sharon L. Hall, Ph.D.; Michael Hatcher,
DrPH; Kimberly Jenkins, BA; Ronald T. Jolly; Barbara M. Riley, RN; Delene
Roberts, MSA; Oscar Tarrago, MD, MPH, CHES; Brian Tencza, MS; Sharon
Wilbur, MA; Dianyi Yu, MD.
Peer Reviewers: Jonathan Borak, MD, DABT; Dave Hewitt, MD.

Disclaimer The state of knowledge regarding the treatment of patients potentially
exposed to hazardous substances in the environment is constantly evolving
and is often uncertain. In this educational monograph, ATSDR has made
diligent effort to ensure the accuracy and currency of the information
presented, but makes no claim that the document comprehensively
addresses all possible situations related to this substance. This monograph is
intended as an educational resource for physicians and other health
professionals in assessing the condition and managing the treatment of
patients potentially exposed to hazardous substances. It is not, however, a
substitute for the professional judgment of a health care provider. The
document must be interpreted in light of specific information regarding the
patient and in conjunction with other sources of authority.
Use of trade names and commercial sources is for identification only and
does not imply endorsement by the Agency for Toxic Substances and Disease
Registry or the U.S. Department of Health and Human Services.
U.S. Department of Health and Human Services

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
Environmental Medicine and Educational Services Branch
Page 2 of 67
How to Use This Course
Introduction The goal of Case Studies in Environmental Medicine (CSEM) is to increase the
primary care provider’s knowledge of hazardous substances in the
environment and to help in evaluation and treating of potentially exposed
patients. This CSEM focuses on chromium toxicity.
Availability Two versions of the Chromium Toxicity CSEM are available.
• The HTML version www.atsdr.cdc.gov/csem/chromium/ provides

content through the Internet.
• The downloadable PDF version provides content in an electronic,
printable format, especially for those who may lack adequate Internet
service.
The HTML version offers interactive exercises and prescriptive feedback to

the user.
Instructions To make the most effective use of this course.
• Take the Initial Check to assess your current knowledge about

chromium toxicity.
• Read the title, learning objectives, text, and key points in each
section.
• Complete the progress check exercises at the end of each section
and check your answers.
• Complete and submit your assessment and posttest response online
if you wish to obtain continuing education credit. Continuing
education certificates can be printed immediately upon completion.
Instructional This course is designed to help you learn efficiently. Topics are clearly
Format labeled so that you can skip sections or quickly scan sections you are already
familiar with. This labeling will also allow you to use this training material as
a handy reference. To help you identify and absorb important content
quickly, each section is structured as follows:
Section
Purpose
Element
Title Serves as a “focus question” that you should be able to answer after
completing the section
Learning Describes specific content addressed in each section and focuses your
Objectives attention on important points
Text Provides the information you need to answer the focus question(s) and
achieve the learning objectives
Key Points Highlights important issues and helps you review
Progress Check Enables you to test yourself to determine whether you have mastered the
learning objectives
Answers Provide feedback to ensure you understand the content and can locate
information in the text
Page 3 of 67
Learning Upon completion of the Chromium Toxicity CSEM, you will be able to
Objectives
Content Area Objectives
Overview • Explain what chromium is.
Exposure • Identify sources of chromium exposure.

Pathways • Identify the routes of exposure to chromium.
Who is at Risk • Identify who is at risk of exposure to chromium.
Standards and • Identify the OSHA permissible exposure limit (PEL) for chromium.
Regulations • Identify EPA’s maximum contaminant level (MCL) for chromium in
drinking water.
Biological Fate • Explain the metabolic difference between Cr(III) and Cr(VI).
Physiologic • List and describe the physiologic effects associated with chromium
Effects exposure.
Clinical • Describe characteristic clinical presentations of patients with acute or

Assessment chronic chromium exposure.
• Identify important aspects of the exposure history.
• Describe characteristic findings on patient examination.
• Identify laboratory tests that can assist with diagnosis of chromium
exposure.
Treatment and • Describe the principal treatment strategies for managing chromium
Management poisoning.
Patient Education • Identify instructions for patient self-care and for clinical follow-up.
and Counseling
Page 4 of 67
Initial Check
Instructions This Initial Check will help you to assess your current knowledge about
chromium toxicity. To take the Initial Check, read the case below, and then
answer the questions that follow.
Case A 35-year-old handyman has chronic skin ulcers and respiratory
irritation.
A 35-year-old man visits your family practice office near a large Midwestern
city. He has complaints of “allergies” and sores on his hands and arms. Over
the past 2 to 3 months, the patient has noticed the onset of runny nose,
sinus drainage, dry cough, and occasional nosebleeds (both nares
intermittently). No prior history of allergies exists. He has also had
occasional nausea and is concerned because the sores and minor skin cuts
on his hands do not seem to heal. The patient denies having fever, chills,
dyspnea, or change in bowel or bladder habits, and he has not noticed
excessive thirst or easy bruising. He recently began losing his appetite and
losing weight without dieting.
With the exception of the complaints mentioned, review of systems is

otherwise unremarkable. The patient has used various over-the-counter
remedies for his respiratory problems without relief. He did note however
significant improvement in symptoms when he visited his sister in Chicago
for 5 weeks at the end of the summer.
Medical history reveals only usual childhood diseases. Other than over-the-
counter (OTC) decongestants, he is taking no medications. He denies use of
illicit drugs, but admits to occasional social use of alcohol. For the last 16
years, he has smoked 1 pack of low-tar cigarettes a day.
The patient has been employed as a mathematics teacher for 13 years; he

usually works summers as a self-employed handyman. His hobbies include
reading and tennis. Two years ago he moved into a ranch-style house
several hundred yards from a small manufacturing plant; a small pond sits
between his house and the plant. The house has central air conditioning
and gas heat; it is supplied with well water and uses a septic sewage
system. Four months ago, the patient began digging up the sewage system
to make repairs. Shortly after he began digging, he first noticed the sores
on his hands and forearms.
Physical examination reveals an alert white male with 10 erythematous

papules of 5-10 millimeters in diameter located bilaterally on the dorsal
forearm and hands; edema of the hands is present. The dermal lesions
show small circular areas with shallow ulcerated centers. Ear, nose, and
throat examination is unremarkable, and chest examination reveals a few
scattered rhonchi that clear with coughing. His liver is slightly enlarged
and tender to palpation. Cardiovascular, genitourinary, rectal, and
neurologic examinations are unremarkable.
Initial laboratory findings include evidence of 2+ proteinuria and hematuria,

and slightly elevated bilirubin, aspartate aminotransferase [AST]; known as
serum glutamic-oxaloacetic transaminase (SGOT), and alanine
Page 5 of 67
aminotransferase (ALT); known as serum glutamic-pyruvic transaminase

(SGPT). Scrapings of the dermal lesions, done with potassium hydroxide
preparation, show no fungal elements on microscopic examination. A nasal
smear for eosinophils is within normal limits.
Initial Check 1. Formulate an active problem list for this patient.
Questions 2. What clues indicate that this case might have an environmental
etiology?
3. What further information will you seek before making a diagnosis?
4. In addition to the patient, who in the case study might be at risk of
chromium exposure?
5. On further questioning, the patient described in the case study relates
that when he had reached several feet in depth while digging to repair
the sewage system, he noticed an oozing from the ground of
sometimes yellowish sometimes greenish water; this persisted
throughout the several weeks of digging. The nearby pond, which is
murky, also has a generally yellow tint, at times with small areas of
greenish color. Suspecting an environmental link, you contact the local
health department. Levels of chromium are found in the pond water
that exceed corresponding health screening values, and the
investigators inform you that the nearby plant is electroplating auto
parts with chromium. Discuss all sources and pathways by which this
patient might be exposed to chromium.
6. Analysis of blood and urine specimens from the patient described in
the case study reveals elevated Cr(III) serum and urine concen-
trations. Assuming that the patient was exposed only to Cr(VI), explain
the presence of Cr(III) in each of these body fluids.
7. Could chromium toxicity account for the symptoms experienced by the
patient described in the case study? Explain.
8. Is the patient at increased risk of chromium-induced lung cancer?
9. Analysis of the tap water in the patient’s home reveals a greenish tinge
and a chromium concentration of 746 micrograms per liter. Your
diagnosis is chromium toxicity. Are there any other tests the patient
should undergo?
10. The patient described in the case study insists on obtaining a hair
analysis. The chromium content of the hair sample is 1,038 parts per
million (ppm). How will you interpret this result?
11. What is the recommended treatment for the patient described in the
case study?
Initial Check 1. A problem list for this patient would include upper and lower respiratory
Answers irritation, multiple skin lesions and edema of the hands, loss of appetite
and weight loss, liver and renal dysfunction, and cigarette smoking.
More information for this answer can be found in the “What are the
physiologic effects of chromium?” section.
2. Information suggesting an environmental etiology includes the following:

onset of the patient’s symptoms coincides with activity outside the usual
routine; in addition, the patient mentions that he first noticed the sores
on his hands and forearms while digging up the sewage system to make
repairs. Another clue to a possible environmental cause is temporary
relief of symptoms when the patient leaves his usual habitat, such as
Page 6 of 67
when he visited Chicago. Proximity of the patient’s home to an industrial

facility (i.e., the electroplating plant) is also an important clue.
More information for this answer can be found in the “Where is chromium
found?” section.
3. You might identify possible causes for the dermal lesions by consulting
with a dermatologist. The cause of the persistent respiratory symptoms
(2 to 3 months) that do not respond to OTC decongestants in a person
with no history of allergies should be pursued. The patient should be
queried about whether the onset of symptoms coincided with the move to
his home, whether odors have emanated from the plant, and so forth.
More information regarding the patient’s observations and activities while
digging up the sewage system may also be helpful.
More information for this answer can be found in the “Clinical assessment
- history and signs and symptoms” section.
4. If effluent from the plant has reached the groundwater, community

residents who drink well water might be at risk. Airborne plant emissions
might have also reached nearby residents. Plant workers who are
exposed to the plating baths and work near them might be receiving
significant exposure.
More information for this answer can be found in the “Who is at risk of
exposure to chromium?” section.
5. The most important pathways for possible chromium exposure in this

case are dermal contact during the unearthing of the sewage system;
inhalation of emissions from the plant or soil particles if the pond dries
up; and ingestion, if the drinking water has been contaminated by
effluents from the plant. Minor inhalation sources of chromium might
include road and cement dust, erosion products of brake linings and
emissions from automotive catalytic converters, and tobacco smoke.
Foodstuffs (ingestion) generally contain extremely low chromium levels.
More information for this answer can be found in the “What are routes of
exposure for chromium?” section.
6. Cr(VI) is a powerful oxidizing agent. In the plasma and cells, it is readily

reduced to Cr(III), which is excreted in the urine.
More information for this answer can be found in the “What is the biologic
fate of chromium in the body?” section.
7. Yes. Persistent dermal ulcers, respiratory tract irritation, and pulmonary

sensitization are all possible effects of chromium exposure.
physiologic effects of chromium exposure?” section.
Page 7 of 67
8. The potential risk of chromium-induced respiratory system cancer from

non-occupational exposure to Cr(VI) must be determined on a case-by-
case basis. It is unlikely that the inhalation chromium exposure of this
patient will cause lung cancer, although it cannot be ruled out. The
patient should be advised to stop smoking cigarettes because smoking
may act synergistically to increase risk and is itself a significant risk
factor for lung cancer.
physiologic effects of chromium exposure?” section.
9. If exposure was recent, chromium levels in blood or urine may be used to

confirm exposure. Renal function should be tested (urinalysis, blood urea
nitrogen, creatinine, and ß2-microglobulin) to determine if renal tubular
damage has occurred.
More information for this answer can be found in the “Clinical
assessment-laboratory tests” section.
10. A result of 1,038 ppm is beyond the range for unexposed persons (50
ppm to 1,000 ppm); however, the sample could have been
environmentally contaminated with chromium from the water during
bathing, or by chromium in ambient air polluted by the plant emissions.
No standard methods exist for obtaining a hair sample or for washing and
preparing the sample for analysis, and these techniques can greatly
influence results. More importantly, no research exists to prove a
correlation between chromium content of hair and exposure levels or
physiologic effects; therefore, the result has no clinical significance.
More information for this answer can be found in the “Clinical
assessment-laboratory tests” section.
11. If the sources of chromium exposure can be eliminated for this patient,
no further treatment would be required, except for the skin lesions.
Topical ascorbic acid has been useful in the treatment of chrome ulcers,
and 1% aluminum acetate wet dressings can be used to treat the
dermatitis.
This patient’s case might be a sentinel for community exposure. You

should contact the local health department, the Occupational Safety and
Health Administration, and U.S. Environmental Protection Agency (EPA)
to report your patient’s adverse effects and discuss your suspicions of the
chromium source. Chromium levels in and around the plant should be
measured. It should be ensured that workers exposed to Cr(VI) are
provided proper protective gear, trained, and medically monitored.
Because EPA does not have an emission standard, it might be difficult to
abate the atmospheric source of chromium. Decontamination of the pond
might require regulatory action and litigation. Residents who use well
water should be encouraged to use an alternative water source for
drinking, cooking, and showering/bathing and any other use that results
in dermal or oral exposure.
More information for this answer can be found in the “How should
patients exposed to chromium be treated and managed?” section.
Page 8 of 67
What Is Chromium?
Learning Upon completion of this section, you will be able to

Objectives
• explain what chromium is.
Definition Chromium is a hard steel-gray metal that is highly resistant to oxidation,

even at high temperatures. It is the sixth most abundant element in the
earth’s crust, where it is combined with iron and oxygen in the form of
chromite ore.
Uses Chromium is used in three basic industries
• metallurgical,
• chemical, and
• refractory (heat-resistant applications).
These industries are the most important industrial sources of chromium in

the atmosphere [EPA 1998; ATSDR 2000].
In the metallurgical industry, chromium is an important component of

stainless steels and various metal alloys. Metal joint prostheses made of
chromium alloys are widely used in clinical orthopedics.
In the chemical industry, chromium is used
• primarily in
o chrome plating,
o leather tanning,
o paint pigments (chromium compounds can be red, yellow,
orange, and green), and
o wood treatment;
• smaller amounts in
o catalysts,
o copy machine toner,
o corrosion inhibitors,
o drilling muds,
o magnetic tapes,
o photographic chemicals,
o safety matches, and
o water treatment.
Refractory uses of chromium include magnesite-chrome firebrick for

metallurgical furnace linings and granular chromite for various other heat-
resistant applications.
Page 9 of 67
Different Chromium exists in a series of oxidation states from -2 to +6 valence. The

Valence States most important stable states are 0 (elemental metal), +3 (trivalent), and +6
(hexavalent).
Chromium in chromite ore is in the trivalent state; industrial processes also

produce the elemental metal and hexavalent chromium.
The health effects of chromium are primarily related to the valence state of
the metal at the time of exposure. Trivalent (Cr[III]) and hexavalent
(Cr[VI]) compounds are thought to be the most biologically significant.
Cr(III) is an essential dietary mineral in low doses. Cr(VI) compounds are
carcinogenic. Cr(VI) is generally considered 1,000 times more toxic than
Cr(III) [EPA 1998; ATSDR 2000; Dayan and Paine 2001].
Essential Cr(III) is an essential dietary nutrient. It is required to potentiate insulin and
Dietary Nutrient for normal glucose metabolism. Cr(III) deficiency has been associated with
• cardiovascular disease,
• decreased lean body mass,
• decreased sperm count,
• elevated percent body fat,
• fasting hyperglycemia,
• glucosuria,
• impaired fertility,
• impaired glucose tolerance, and
• maturity-onset diabetes.
Cr(III) is found in most fresh foods and drinking water. Dietary sources rich
in Cr(III) include
• breads,
• cereals,
• fish,
• fresh vegetables,
• meats, and
• spices.
Other significant sources of Cr(III) are mineral supplements, brewer’s yeast,

and beer.
The National Academy of Sciences has established a safe and adequate daily
intake for Cr(III) in adults of 50 -200 micrograms per day. On the average,
adults in the United States take in an estimated 60-80 micrograms of Cr(III)
per day in food. Therefore, many people’s diets may not provide enough
Cr(III) [ATSDR 2000].
The biologically active form of an organic Cr(III) complex, often referred to

as glucose tolerance factor (GTF), is believed to function by facilitating the
interaction of insulin with its cellular receptor sites. Studies have shown that
the Cr(III) supplementation in deficient and marginally deficient subjects can
result in the rapid reversal of many of the symptoms of chromium-deficiency
[Cohen, Kargacin et al. 1993; Mertz 1993].
Page 10 of 67
Key Points • Chromium exists in three common stable valence states: chromium
(0), (III), and (VI).
• Cr(III) is an essential dietary nutrient. Its deficiency in the body has
been associated with diabetes, infertility, and cardiovascular disease.
• Cr(VI) is carcinogenic.
• The metallurgical, chemical, and refractory industries are the
fundamental users of chromium.
Progress Check 1. Which of the following statements is correct?
A. Chromium is highly resistant to reduction.

B. Cr(III) is an essential dietary nutrient.
C. The health effects of chromium are not related to the valence state of
the metal.
D. None of the above.
To review relevant content, see “Essential Dietary Nutrient” in this

section.
Page 11 of 67
Answers 1. The correct answer is B. Cr(III) is an essential dietary mineral in

low doses. It is required to potentiate insulin and for normal
glucose metabolism. Cr(III) deficiency has been associated with
many chronic diseases such as diabetes, infertility, and
cardiovascular disease.
Page 12 of 67
Where Is Chromium Found?

Objectives
• identify sources of chromium exposure.
Introduction Naturally occurring chromium is usually present as trivalent Cr(III).

Hexavalent Cr(VI) in the environment is almost totally derived from human
activities [WHO 1990].
Air According to the Toxics Release Inventory, in 1997, the estimated releases
Contamination of chromium were 706,204 pounds to the air from 3,391 large processing
facilities which accounted for about 2.2% of total environmental releases.
Cr(III) and Cr(VI) are released to the environment primarily from stationary
point sources (facilities that are identified individually by name and location)
resulting from human activities. The estimates of atmospheric chromium
emissions in 1976 and 1980 in the Los Angeles, CA and Houston, TX areas
indicate that emissions from stationary fuel combustion are about 46-47% of
the total, and emissions from the metal industry range from 26 to 45% of
the total [ATSDR 2000].
Coal and oil combustion contribute an estimated 1,723 metric tons of

chromium per year in atmospheric emissions; however, only 0.2% of this
chromium is Cr(VI). In contrast, chrome-plating sources are estimated to
contribute 700 metric tons of chromium per year to atmospheric pollution,
100% of which is believed to be Cr(VI) [ATSDR 2000].
Cr(III) in the air does not undergo any reaction. Cr(VI) in the air eventually
reacts with dust particles or other pollutants to form Cr(III). However, the
exact nature of such atmospheric reactions has not been studied extensively
[EPA 1998].
Water According to the Toxics Release Inventory, in 1997, the estimated releases
Contamination of chromium was 111,384 pounds to water from 3,391 large processing
facilities which accounted for about 0.3% of total environmental releases
[ATSDR 2000].
Electroplating, leather tanning, and textile industries release relatively large

amounts of chromium in surface waters. Leaching from topsoil and rocks is
the most important natural source of chromium entry into bodies of water.
Solid wastes from chromate-processing facilities, when disposed of
improperly in landfills, can be sources of contamination for groundwater,
where the chromium residence time might be several years.
A survey conducted from 1974 to 1975 provides estimates of chromium

concentrations in U.S. drinking water. The survey reported the concentration
of chromium in tap water in U.S. households was from 0.4 to 8.0
micrograms per liter (μg/L). [ATSDR 2000] (EPA’s maximum contaminant
level for chromium in drinking water is 100 μg/L.)
Soil According to the Toxics Release Inventory, in 1997 the estimated releases of
Contamination chromium was 30,862,235 pounds to soil from 3,391 large processing
facilities accounted for about 94.1% of total environmental releases [ATSDR
Page 13 of 67
2000].
Total chromium has been identified in 939 soil and 472 sediment samples
collected from 1,036 National Priority Lists (NPL) hazardous waste sites
[HazDat 2000].
Chromium waste slag containing potentially hazardous levels of Cr(VI)

compounds was used as fill material at more than 160 residential, industrial,
and recreational sites. Persons living or working in the vicinity of the sites
may have been exposed through inhalation, ingestion, or skin contact with
contaminated soils and dusts [Fagliano, Savrin et al. 1997].
Community exposure from this fill occurred in a variety of ways. Wind

erosion of the soil could have made slag particles airborne, increasing the
opportunity for inhalation of chromium. Chromium compounds leached by
rainwater could have migrated through cracks in soil, asphalt roadways, and
masonry walls, forming high-content chromium crystals on their surfaces. In
soil and roadways, these particles might have been eroded by wind and foot
traffic and carried as chromium-laden dust into homes and workplaces.
Children playing in areas where the slag was used as fill might also have
been exposed through skin contact with chromium-contaminated dust, dirt,
and puddles and /or ingestion of contaminated soil.
Other Other environmental sources of chromium are cement-producing plants
Environmental (cement contains chromium), the wearing down of asbestos linings that
Sources contain chromium, emissions of chromium-based automotive catalytic
converters, and tobacco smoke.
The general population is exposed to chromium by eating food or food

supplements, drinking water, and inhaling air that contain chromium. The
mean daily dietary intake of chromium from air, water, and food is estimated
to be <0.2-0.4, 2.0, and 60 micrograms, respectively [ATSDR 2000].
One study found increased blood chromium level after total hip replacement
using metal-metal pairings where metal ions of the alloys are released
[Schaffer, Pilger et al. 1999].
Summary of Environmental and Occupational Sources of Chromium Exposure
Environmental Environmental sources of chromium include

Sources
• airborne emissions from chemical plants and incineration facilities,
• cement dust,
• contaminated landfill,
• effluents from chemical plants,
• asbestos lining erosion,
• road dust from catalytic converter erosion and asbestos brakes,
• tobacco smoke, and
• topsoil and rocks.
Page 14 of 67
Occupational Occupational sources of chromium include

Sources
• anti-algae agents,
• antifreeze,
• cement ,
• chrome alloy production,
• chrome electroplating (soluble Cr[VI]),
• copier servicing,
• glassmaking,
• leather tanning (soluble Cr[III]),
• paints/pigments (insoluble Cr[VI]),
• photoengraving,
• porcelain and ceramics manufacturing,
• production of high-fidelity magnetic audio tapes,
• tattooing,
• textile manufacturing,
• welding of alloys or steel, and
• wood preservatives, i.e. Acid Copper Chromate.
Key Points • Chromium is released to air primarily by combustion processes and

metal industries.
• Non-occupational sources of chromium include contaminated soil, air,
water, smoking, and diet.
Progress Check 2. What sources does chromium contamination result from?
A. Stationary fuel combustion (residential, commercial, and industrial).

B. Leaching from topsoil and rocks is the most important natural source
of chromium entry into bodies of water.
C. Releases to soil from metal processing facilities.
D. All of the above.
To review relevant content, see “Air Contamination,” “Water

Contamination,” and “Soil Contamination” in this section.
Page 15 of 67
Answers 2. The correct answer is D. Cr(III) and Cr(VI) are released to the
environment primarily from stationary point sources (facilities that are
identified individually by name and location) resulting from human
activities. The estimates of atmospheric chromium emission in 1976
and 1980 in the Los Angeles, CA and Houston, TX areas indicate that
emissions from stationary fuel combustion are about 46-47% of the
total environmental releases. According to the Toxics Release
Inventory, in 1997, the estimated releases of chromium of 30,862,235
pounds to soil from 3,391 large processing facilities accounted for
about 94.1% of total environmental releases. Leaching from topsoil
and rocks is the most important natural source of chromium entry into
bodies of water.
Page 16 of 67
What Are the Routes of Exposure for Chromium?

Objectives
• identify the routes of exposure to chromium.
Introduction The entry routes of chromium into the human body are inhalation, ingestion,
and dermal absorption. Occupational exposure generally occurs through
inhalation and dermal contact, whereas the general population is exposed
most often by ingestion through chromium content in soil, food, and water.
Inhalation After human exposure to Cr(III) by inhalation, urinary concentrations of
chromium were found to be increased indicating respiratory absorption
[Aitio, Jarvisalo et al. 1984; Foa, Riboldi et al. 1988; Dayan and Paine 2001].
Data from a few animal experiments indicate that with equal solubility,
Cr(VI) compounds are absorbed more readily than Cr(III) compounds,
probably because Cr(VI) readily penetrates cell membranes [Mertz 1969;
Wiegand, Ottenwalder et al. 1984].
Cr(VI) is reduced to Cr(III) in the lower respiratory tract by the

epithelial lining fluid and by pulmonary alveolar macrophages [Dayan
and Paine 2001]. One study showed that at equivalent numbers of cells,
the reducing efficiency of alveolar macrophages by biochemical
mechanisms was significantly greater in tobacco smokers than in
nonsmokers [Petrilli, Rossi et al. 1986].
Ingestion In general, Cr(VI) compounds are better absorbed through the intestinal
mucosa than the Cr(III) compounds. However, due to the actions of stomach
acid and other components within the gastrointestinal tract, most of an
ingested Cr(VI) dosage is converted to Cr(III) [Cohen, Kargacin et al. 1993].
In humans and animals, less than 1% of inorganic Cr(III) and about 10% of
inorganic Cr(VI) are absorbed from the gut; the latter amount is slightly
higher in a fasting state [Donaldson and Barreras 1966; Dayan and Paine
2001].
Skin Data from volunteers and indirect evidence from occupational studies
indicate that absorption of Cr(VI) compounds can occur through intact skin
[Baranowska-Dutkiewicz 1981]. Studies in experimental animals showed
poor absorption of Cr(III) compounds following dermal route [Dayan and
Paine 2001].
Key Points • Occupational exposure generally occurs through inhalation and dermal
contact, whereas the general population is exposed most often by
ingestion through chromium content in soil, food, and water.
• The majority of Cr(VI) that enters the body via inhalation or ingestion
is quickly reduced to Cr(III).
Page 17 of 67
Progress Check 3. Which of following statements regarding exposure pathway is correct?
A. Cr(VI) and Cr(III) have equal capacity to be absorbed through any

routes into the human body.
B. Cigarette smoking has no impact on absorption of chromium.
C. The general population is exposed most often by ingestion through
chromium content in soil, food, and water.
To review relevant content, see “Introduction” in this section.
Page 18 of 67
Answers 3. The correct answer is C. You can be exposed to chromium by breathing

air, drinking water, or eating food containing chromium or through skin
contact with chromium or chromium compounds. The level of
chromium in air and water is generally low. People who work in
industries that process or use chromium or chromium compounds can
be exposed to higher-than-normal levels of chromium.
Page 19 of 67
Who Is at Risk of Exposure to Chromium?

Objectives
• identify who is at risk of exposure to chromium.
Introduction Chromium is one of the most widely used industrial metals. Several million
workers worldwide are estimated to be exposed to chromium compounds in
an array of industries such as pigment production, chrome plating, stainless
steel welding, and leather tanning. Additionally, it is one of the major
contaminants in various hazardous waste sites worldwide, including the
Superfund sites in the United States [EPA 2002; Medeiros, Rodrigues et al.
2003].
Worker Workers in industries that use chromium are at increased risk of chromium’s
Exposure adverse health effects. Those workers at greatest risk are those involved in
stainless steel welding, chromate production, chrome plating, and chrome
pigment industries, where exposure is primarily to Cr(VI) via inhalation of
aerosols.
An estimated 558,000 workers in the United States are potentially exposed

to chromium and chromium-containing compounds in the workplace. In
many occupations, workers are exposed to both trivalent chromium (Cr[III])
and Cr(VI), as soluble and insoluble materials [ATSDR 2000; OSHA 2006].
General Public The general population is exposed to chromium by inhaling ambient air,
ingesting food, and drinking water containing chromium.
The presence of chromium compounds at hazardous waste sites can

contribute to the exposure of populations residing or working nearby such
sites. These populations may be exposed through to air containing
particulates or mists of Cr(VI) compounds, through drinking water if soluble
forms of Cr(VI) leach into groundwater, or through skin contact with soil at
hazardous waste sites.
The potential for exposure to Cr(VI) at hazardous waste sites must be

determined on a case-by-case basis.
Key Points • Workers in industries producing and using chromium are at greatest
risk of its adverse effects.
• The general population is exposed to chromium by inhaling ambient
air, ingesting food, and drinking water containing chromium.
Progress Check 4. Of the following, who is at risk of chromium exposure?
A. Residents near chromate production facilities.

B. Workers in industries that use chromium.
C. Tobacco smokers.
To review relevant content, see “Worker Exposure” and “General Public”

in this section.
Page 20 of 67
Answers 4. The correct answer is D. Workers in industries producing and using

chromium are at greatest risk of its adverse effects. Residents near
chromate production facilities might be exposed to higher-than-
background levels of Cr(VI). In addition, because tobacco contains
chromium, tobacco smokers bear the risk of exposure to chromium as
well.
Page 21 of 67
What are the Standards and Regulations for Chromium Exposure?

Objectives
• Identify the OSHA permissible exposure limit (PEL) for chromium.
• Identify EPA’s maximum contaminant level (MCL) for chromium in
drinking water.
Introduction The government has developed regulations and guidelines for chromium.
These are designed to protect the public from potential adverse health
effects.
Workplace OSHA
Guidelines
The Occupational Safety and Health Administration (OSHA) has established
an 8-hour time-weighted average (TWA) exposure limit of 5 micrograms of
Cr(VI) per cubic meter of air (5 μg/m³). This is a considerable reduction from
the previous permissible exposure limit (PEL) of 52 μg/m³ [Federal Register
2006].
OSHA’s standard is based upon the best evidence currently available that at
the previous PEL for Cr(VI), workers face a significant risk to material
impairment of their health. The evidence in the record for this rulemaking
indicates that workers exposed to Cr(VI) are at an increased risk of
developing lung cancer. The record also indicates that occupational exposure
to Cr(VI) may result in asthma and damage to the nasal epithelia and skin.
[Federal Register 2006].
The final rule also contains ancillary provisions for worker protection such as
• requirements for exposure determination,
• preferred exposure control methods, including a compliance alternative
for a small sector for which the new PEL is infeasible,
• respiratory protection,
• protective clothing and equipment,
• hygiene areas and practices,
• medical surveillance,
• record keeping, and
• start-up dates that include four years for the implementation of
engineering controls to meet the PEL [Federal Register 2006].
For Cr(II) and Cr(III) compounds, the PEL is an 8-hour TWA of 500 μg
Cr/m³. For chromium metal and for insoluble compounds, the PEL is 1,000
μg Cr/m³[OSHA 2006].
NIOSH
The National Institute for Occupational Safety and Health (NIOSH) has
recommended a 10-hour TWA exposure limit for all Cr(VI) compounds of 1
μg Cr(VI)/m³. For chromium metal and Cr (II) and Cr(III) compounds, the
recommended exposure limit is 500 μg /m³ as an 10-hour TWA [NIOSH
2005].
On the basis of current evidence, NIOSH considers all Cr(VI) compounds

potential occupational carcinogens.
Page 22 of 67
Environmental Air
Guidelines
The U.S. Environmental Protection Agency (EPA) regulates chromium
emissions under the Clean Air Act of 1990. EPA uses technology-based
standards for categories of industries, rather than numerical emissions
standards, to reduce chromium levels in ambient air. These maximum
achievable control technology (MACT) standards are based on emissions
levels already achieved by the best-performing similar facilities.
Drinking Water
EPA has an enforceable maximum contaminant level of total chromium in

drinking water of 100 μg/L (100 ppb) for public water systems [EPA 1999 h].
Table 1. Regulations and Guidelines for Chromium

Agency Focus Level Comments
American Conference of Air: workplace
10 μg/m³ as Cr Advisory; TWA* to avoid
Governmental
carcinogenic risk from insoluble
Industrial Hygienists
Cr(VI) compounds
50 μg/m³ as Cr TWA for water-soluble Cr(VI)

compounds
500 μg/m³ as Cr TWA for chromium metal and

Cr(III) compounds
National Institute for Air: workplace 1 μg/m³ as Cr Advisory; TWA (10-hour) for
Occupational Safety chromic acid and all Cr(VI)
and Health compounds
500 μg/m³ as Cr Advisory; TWA (10-hour) for

chromium metal and Cr(II) and
Cr(III) compounds
Occupational Safety Air: workplace 5 μg/m³ as Cr Regulation; PEL† for chromic

and Health acid and chromates, (8-hour
Administration TWA)
500 μg/m³ as Cr PEL for Cr(II) and Cr(III)

compounds (8-hour TWA)
1,000 μg/m³ as Cr PEL for chromium metal and

insoluble compounds (8-hour
TWA)
Page 23 of 67
Environmental Air: Not available Chromium is listed as a

Protection Agency environment hazardous pollutant
Drinking 100 μg/L Regulation; current MCL‡ for

water total chromium
*TWA (time-weighted average): TWA concentration for a normal workday and a 40-hour
workweek to which nearly all workers may be repeatedly exposed.
†PEL (permissible exposure limit): highest level of chromium in air, to which a worker may be
exposed, averaged over an 8-hour workday.
‡MCL (maximum contaminant level) enforceable level for drinking water.
Key Points • OSHA has established an 8-hour time-weighted average (TWA)

exposure limit of 5 micrograms of Cr(VI) per cubic meter of air (5
μg/m³). This is a considerable reduction from the previous PEL of 52
μg/m³.
• The current EPA maximum contaminant level for chromium in drinking
water is 100 μg/L.
Progress Check 5. OSHA’s PEL for Cr(VI) (chromic acid and chromates) in the workplace is
which of the following?
A. 5 μg CrO3/m³.
B. 10 μg CrO3/m³.
C. 52 μg CrO3/m³.
D. 100 μg CrO3/m³.
To review relevant content, see “Table 1” in this section.
Page 24 of 67
Answers 5. The correct answer is A. OSHA has mandated PEL ceiling of 5 μg /m³
for chromic acid and chromates.
Page 25 of 67
What Is the Biologic Fate of Chromium in the Body?

Objectives
• explain the metabolic difference between Cr(III) and Cr(VI).
Introduction In vivo reduction of Cr(VI) to Cr(III) has been widely studied. Ingested
Cr(VI) is efficiently reduced to the Cr(III) by the gastric juices [De Flora,
Badolati et al. 1987]. Cr(VI) can also be reduced to the Cr(III) in the
epithelial lining fluid of the lungs by ascorbate and glutathione (Petrilli, Rossi
et al. 1986; Suzuki and Fukuda 1990).
Absorption Rates of chromium uptake from the gastrointestinal tract are relatively low
and depend on a number of factors, including
• valence state (with Cr[VI] more readily absorbed than Cr[III]),
• the chemical form (with organic chromium more readily absorbed than
inorganic chromium),
• the water solubility of the compound, and
• gastrointestinal transit time.
Once absorbed into the bloodstream, Cr(VI) is rapidly taken up by

erythrocytes after absorption and reduced to Cr(III) inside the red blood
cells. In contrast, Cr(III) does not readily cross red blood cell membranes,
but binds directly to transferrin, an iron-transporting protein in the plasma
(EPA 1998; ATSDR 2000; Dayan and Paine 2001].
Reduction of Cr(VI) in the red blood cells occurs by the action of glutathione.
Since the red blood cell membrane is permeable to Cr(VI) but not Cr(III),
the Cr(III) formed by reduction of Cr(VI) is essentially trapped within the red
blood cell. Eventually the diffusion of Cr(VI), the reduction to Cr(III), and
complexing to nucleic acids and proteins within the cell will cause the
concentration equilibrium to change [ATSDR 2000].
Regardless of the source, Cr(III) is widely distributed in the body and

accounts for most of the chromium in plasma or tissues. The greatest uptake
of Cr(III) as a protein complex is via bone marrow, lungs, lymph nodes,
spleen, kidney, and liver. Autopsies reveal that chromium levels in the lungs
are consistently higher than levels in other organs [ATSDR 2000].
Metabolic The first defense against Cr(VI) after oral exposure is the reduction of Cr(VI)
Pathways to Cr(III) in the gastric environment where gastric fluid [De Flora, Badolati et
al. 1987] and ascorbate [Samitz 1970] play important roles [ATSDR 2000].
Excretion of absorbed chromium occurs primarily via urine. In humans, the

kidney excretes about 60% of an absorbed Cr(VI) dose in the form of Cr(III)
within 8 hours of ingestion. Approximately 10% of an absorbed dose is
eliminated by biliary excretion, with smaller amounts excreted in hair, nails,
milk, and sweat [Kiilunen, Kivisto et al. 1983; ATSDR 2000].
Clearance from plasma is generally rapid (within hours), whereas elimination

from tissues is slower (with a half-life of several days). Doses of Cr(VI)
administered to volunteers were more rapidly eliminated than doses of
Cr(III) [ATSDR 2000].
Page 26 of 67
Key Points • Cr(VI) is better absorbed from the lungs, gut, and skin than is Cr(III).
• After absorption, Cr(VI) is reduced to Cr(III).
• The difference in bioavailability and bioactivity between Cr(III) and
Cr(VI) might account for the differences in toxicity. Cr(III) is an
essential dietary nutrient whereas Cr(VI) poses a significant risk of
lung cancer.
• Cr(III) is excreted, primarily in the urine.
Progress Check 6. Which of the following statements about metabolism of an absorbed dose
of chromium is correct?
A. Cr(VI) is rapidly taken up by erythrocytes after absorption and

reduced to Cr(III) inside the red blood cells.
B. Cr(III) is widely distributed in the body and accounts for most of the
chromium in plasma or tissues.
C. Excretion of absorbed chromium occurs primarily via urine.
To review relevant content, see “Absorption” and “Metabolic Pathways” in

this section.
Page 27 of 67
Answers 6. The correct answer is D. Once absorbed into the bloodstream, Cr(VI) is
rapidly taken up by erythrocytes after absorption and reduced to
Cr(III) inside the red blood cells. Regardless of the source, Cr(III) is
widely distributed in the body and accounts for most of the chromium
in plasma or tissues. The greatest uptake of Cr(III) as a protein
complex is via bone marrow, lungs, lymph nodes, spleen, kidney, and
liver. Excretion of absorbed chromium occurs primarily via urine, with
no major retention in organs.
Page 28 of 67
What Are the Physiologic Effects of Chromium Exposure?

Objectives
• describe physiologic effects, other than cancer, associated with
chromium exposure and
• describe the carcinogenic effects associated with Cr(VI) exposure.
Introduction Major factors governing the toxicity of chromium compounds are oxidation
state and solubility. Cr(VI) compounds, which are powerful oxidizing agents
and thus tend to be irritating and corrosive, appear to be much more toxic
systemically than Cr(III) compounds, given similar amounts and solubilities.
Although mechanisms of biological interaction are uncertain, this variation in
toxicity may be related to the ease with which Cr(VI) can pass through cell
membranes and its subsequent intracellular reduction to reactive
intermediates.
Mechanism of Since Cr(III) is poorly absorbed by any route, the toxicity of chromium is
Chromium mainly attributable to the Cr(VI) form. It can be absorbed by the lung and
Toxicity gastrointestinal tract, and even to a certain extent by intact skin.
The reduction of Cr(VI) is considered to serve as a detoxification process

when it occurs at a distance from the target site for toxic or genotoxic effect
while reduction of Cr(VI) may serve to activate chromium toxicity if it takes
place in or near the cell nucleus of target organs [Dayan and Paine 2001]. If
Cr(VI) is reduced to Cr(III) extracellularly, this form of the metal is not
readily transported into cells and so toxicity is not observed. The balance
that exists between extracellular Cr(VI) and intracellular Cr(III) is what
ultimately dictates the amounts and rates at which Cr(VI) can enter cells and
impart its toxic effects [Cohen, Kargacin et al. 1993].
Cr(VI) enters many types of cells and under physiological conditions can be
reduced by hydrogen peroxide (H2O2), glutathione (GSH) reductase, ascorbic
acid, and GSH to produce reactive intermediates, including Cr(V), Cr(IV),
thiylradicals, hydroxyl radicals, and ultimately, Cr(III). Any of these species
could attack DNA, proteins, and membrane lipids, thereby disrupting cellular
integrity and functions [De Mattia, Bravi et al. 2004].
Respiratory Occupational exposures often include mixed exposure to both Cr(III) and
Effects Cr(VI) [EPA 1998].
Human occupational experience clearly indicates that, when inhaled,

chromium compounds are respiratory tract irritants, resulting in airway
irritation, airway obstruction, and lung, nasal, or sinus cancer. Dose,
exposure duration, and the specific compound involved can determine
chromium’s adverse health effects.
Pulmonary irritant effects following inhalation of chromium dust can include
• asthma,
• chronic bronchitis,
• chronic irritation,
• chronic pharyngitis,
• chronic rhinitis,
Page 29 of 67
• congestion and hyperemia,

• polyps of the upper respiratory tract,
• tracheobronchitis, and
• ulceration of the nasal mucosa with possible septal perforation
[Lindberg and Hedenstierna 1983; Dayan and Paine 2001].
Radiographic analysis from several reports revealed enlargement of the hilar

region and lymph nodes [PHS 1953; Sluis-Cremer and du Toit 1968].
Consistent associations have been found between employment in the
chromium industries and significant risk for respiratory cancer (see
Carcinogenic Effects).
A delayed anaphylactoid reaction was reported in a male worker

occupationally exposed to chromium vapors from Cr(VI) trioxide baths and
chromium fumes from stainless steel welding. A subsequent inhalation
challenge with sodium chromate resulted in a reaction including late-onset
urticaria, angioedema, and bronchospasm accompanied by tripling of plasma
histamine levels [Moller, Brooks et al. 1986].
Many cases of nasal mucosa injury (inflamed mucosa, ulcerated septum, and
perforated septum) have been reported in workers exposed to Cr(VI) in
chrome-plating plants and tanneries [ATSDR 2000]. A 1983 study of 43
chrome-plating plants in Sweden, where workers were exposed almost
exclusively to Cr(VI) acid, revealed that all workers with nasal mucosa
ulceration or perforation were periodically exposed to at least 20 micrograms
per cubic meter (μg/m³) when working near the plating baths (The newest
U.S. permissible exposure level in the workplace for chromates and chromic
acid is 5 μg/m³ as a ceiling). The period of exposure for workers
experiencing nasal mucosal ulceration varied from 5 months to 10 years
[Lindberg and Hedenstierna 1983]. A recent epidemiological study of U.S.
workers found that the median time from date first employed to date of first
diagnosis of nasal ulceration was less than a month; the median Cr(VI)
concentration was similar to concentrations reported in the Swedish study
[Gibb, Lees et al. 2000].
Occupational exposure to Cr(III) has also been associated with respiratory

effects. One man developed coughing, wheezing, and decreased forced
volume after an inhalation exposure to a sample of Cr(III) sulfate [Novey,
Habib et al. 1983]. In an industrial hygiene survey of 60 ferrochromium
workers exposed to Cr(III) and Cr(VI) (0.02-0.19 mg total chromium/m³)
conducted in 1975, appreciably higher incidences of subjective symptoms of
coughing, wheezing, and dyspnea were reported compared with controls.
However, due to the tobacco smoking that cannot be excluded as a
confounding factor, the increase in subjective respiratory symptoms and
decreased pulmonary function parameters cannot be unequivocally be
attributed to chromium exposure [Langard S 1980].
The respiratory system in animals is also a primary target for inhalation

exposure to chromium. Histological examination of the lung tissue revealed
alterations representing mild nonspecific irritation after exposure to 0.9 or 25
mg Cr(III) trichloride for 30 min [Henderson, Rebar et al. 1979].
Page 30 of 67
An extensive epidemiological survey was conducted of housewives who lived

in an area of Tokyo, Japan, in which contamination from chromium slag at a
construction site was discovered in 1973. The exposed population reported a
higher incidence of subjective complaints of nasal irritation than the control
population in the early years of the study, buy in later years the difference
between the two groups became progressively less [ATSDR 2000].
Skin Effects Dermal exposure to chromium has been demonstrated to produce irritant
and allergic contact dermatitis [Polak 1983; Bruynzeel, Hennipman et al.
1988]. Primary irritant dermatitis is related to the direct cytotoxic properties
of chromium, while allergic contact dermatitis is an inflammatory response
mediated by the immune system. Allergic contact dermatitis is a cell-
mediated immune response that occurs in a two-step process. In the first
step (induction), chromium is absorbed into the skin and triggers the next
step - an immune response (sensitization). Sensitized individuals will exhibit
an allergic dermatitis response when exposed to chromium above a
threshold level [Polak 1983]. Localized erythematous or vesicular lesions at
points of contact or generalized eczematous dermatitis should suggest
sensitization [Lewis 2004].
Chromium allergic dermatitis is characterized by symptoms of
• dryness,
• erythema,
• fissuring,
• papules,
• scaling,
• small vesicles, and
• swelling [MacKie 1981; Adams 1990].
Solubility and pH appear to be the primary determinants of the capacity of

individual chromium compounds to elicit an allergic response [Polak, Turk et
al. 1973; Fregert and Fregert 1981]. The low solubility Cr(III) compounds
are much less efficient contact allergens than Cr(VI) [Spruit, van Neer et al.
1966].
Penetration of the skin will cause painless erosive ulceration (“chrome

holes”) with delayed healing. These commonly occur on the fingers,
knuckles, and forearms. The characteristic chrome sore begins as a papule,
forming an ulcer with raised hard edges. Ulcers can penetrate deep into soft
tissue or become the site of secondary infection, but are not known to lead
to malignancy [Deng, Fleeger et al. 1990; Geller 2001; Lewis 2004; Meditext
2005].
In addition, occupational exposure Cr(VI) compounds has been associated

with effects on the skin, nasal septum, and eardrum [Gibb, Lees et al. 2000].
Chromium is one of the most common skin sensitizers and often causes skin
sensitizing effect in the general public. A possible source of chromium
exposure is waste dumps for chromate-producing plants causing local air or
water pollution.
Page 31 of 67
Carcinogenic Occupational exposure to Cr(VI) compounds in a number of industries has

Effects been associated with increased risk of respiratory system cancers [ATSDR
2000].
Baetjer was one of the first to review the literature presented prior to 1950
on the occurrence of cancer in chromate-exposed workers [Baetjer 1950].
The first epidemiological study of chromate production workers in the United

States that demonstrated an association with lung cancer was conducted
with 1,445 workers in seven plants engaged in the extraction of chromates
from ore from 1930 to 1947. The percentage death due to cancer of the
respiratory system was 21.8%; the percentage expected was 1.4% [Machle
and Gregorius 1948].
In another key epidemiological study involving workers at a chromate

production plant who had worked at the plant for more than 1 year from
1931 to 1949, the percentage of deaths due to lung cancer was 18.2%; the
percentage expected was 1.2%. For the 332 workers first employed from
1931 to 1937, the percentage of deaths due to lung cancer was close to 60%
of all cancer deaths, with a latency period of approximately 30 years
[Mancuso 1951; Mancuso 1975].
Studies of workers in the chromium pigment, chrome-plating, and

ferrochromium industries showed a statistically significant association
between worker exposure to Cr(VI) and lung cancer [Langard and Norseth
1975; Sheffet, Thind et al. 1982; Frentzel-Beyme 1983; Langard and
Vigander 1983; Davies 1984; ATSDR 2000].
In addition to lung cancer, a number of epidemiological studies of workers in

chromate industries also showed significantly increased risk for nasal and
sinus cancers [ATSDR 2000].
On the basis of these and other studies, the U.S. Environmental Protection
Agency (EPA) and the International Agency for Research on Cancer (IARC)
have classified inhaled Cr(VI) as a known human carcinogen [IARC 1990;
EPA 1998]. The World Health Organization (WHO) has determined that
Cr(VI) is a human carcinogen. The Department of Health and Human
Services (DHHS) has determined that Cr(VI) compounds are known to cause
cancer in humans [ATSDR 2000].
Lung cancer risk in relation to airborne levels of Cr(VI) was analyzed for
chromium chemical production workers and a dose-response relationship
was observed in that long-term workers had a higher lung cancer risk than
short-term workers [Hayes, Lilienfeld et al. 1979]. An analysis of lung cancer
risk suggests a potential excess risk of death from lung cancer among U.S.
workers exposed to the previous permissible exposure limit (PEL) for Cr(VI)
of 52 µg/m³ [Braver, Infante et al. 1985]. More recent studies also disclosed
excess risk of lung cancer death resulting from occupational exposure to
Cr(VI) compounds [Gibb, Lees et al. 2000; Park, Bena et al. 2004].
Page 32 of 67
Stratified analysis of lung cancer mortality showed a trend of increasing

mortality with higher cumulative exposure levels. The analyses stratified by
duration of employment and time since first exposure indicate a consistency
of results among those employed the longest and with the longest elapsed
time since first exposure. The latter suggests a latency period of
approximately 20 -35 years, which is compatible with other research
[Luippold, Mundt et al. 2003].
Carcinogenicity appears to be associated with the inhalation of the less

soluble/insoluble Cr(VI) compounds. The toxicology of Cr(VI) does not reside
with the elemental form. It varies greatly among a wide variety of very
different Cr(VI) compounds [Katz and Salem 1993].
Epidemiological evidence strongly points to Cr(VI) as the agent in

carcinogenesis. Solubility and other characteristics of chromium, such as
size, crystal modification, surface charge, and the ability to be phagocytized,
compounds might be important in determining cancer risk [Norseth 1981;
Langard 1983; Gad 1989].
In addition to the occupational studies, a retrospective environmental

epidemiological study was conducted in residents of a county in Sweden
where two ferrochromium alloy industries are located. No indication was
found that residence near these industries is associated with an increased
risk of lung cancer [Axelsson, Rylander et al. 1980].
A number of chronic inhalation studies provide evidence that Cr(VI) is

carcinogenic in animals [ATSDR 2000].
No evidence exists to indicate that Cr(III) can cause cancer in animals or

humans [IARC 1990; EPA 1998].
Mechanism of Cr(VI)-induced carcinogenicity.
The mechanism(s) of Cr(VI)-induced carcinogenicity is not completely

understood. The toxicity of chromium within the cell may result from damage
to cellular components during the hexavalent to trivalent chromium
reduction process, by generation of free radicals, including DNA damage
[ATSDR 2000]. Recent studies indicate a biological relevance of non-
oxidative mechanisms in Cr(VI) carcinogenesis [Zhitkovich, Song et al.
2001].
Page 33 of 67
Renal Effects Renal effects after inhalation or oral exposure to Cr(VI) compounds have
been reported.
Although glomerular injury has been noted in chromium workers, the

predominant renal injury is tubular, with low doses acting specifically on the
proximal convoluted tubules. Injury to the brush border membrane is a
feature of chromate nephropathy [Kirschbaum, Sprinkel et al. 1981]. Severe
poisoning can lead to acute tubular necrosis and acute renal failure [Sharma,
Singhal et al. 1978]. Low-dose chronic Cr(VI) exposure typically results only
in transient renal effects. Elevated urinary ß2-microglobulin levels (an
indicator of renal tubular damage) have been found in chrome platers, and
higher levels have generally been observed in younger persons exposed to
higher Cr(VI) concentrations [Lindberg and Vesterberg 1983]. Sensitive
immunochemical techniques for the measurement of specific proteins in the
urine have been used for the early detection of kidney damage, a possible
threshold having been indicated at exposure levels yielding 15 µg/g
creatinine in urine [Franchini and Mutti 1988].
Occupational exposure to Cr(III) does not appear to be associated with renal

effects (ATSDR 2000]. No renal impairment based on urinary albumin,
retinol binding protein, and renal tubular antigens was found in 236 workers
employed in the ferrochromium production industry [Foa, Riboldi et al.
1988].
Hepatic Effects Cr(VI) has been reported to cause severe liver effects in four of five workers
exposed to chromium trioxide in the chrome plating industry. The reported
liver effects include derangement of the liver cells, necrosis, lymphocytic and
histocytic infiltration, and increases in Kupffer cells [Pascale, Waldstein et al.
1952].
Cases of hepatic effects after oral exposure to Cr(VI) compounds have also
been reported. Elevated liver enzyme levels were reported flowing ingestion
of 150 mL solution containing 22.5 g potassium dichrome. [Kolaciski,
Kostrzewski et al. 1999] Hepatomegaly [Michie, Hayhurst et al. 1991; Meert,
Ellis et al. 1994] and hepatic failure [Loubieres, de Lassence et al. 1999;
Stift, Friedl et al. 2000] have also been noted in the cases of acute
poisoning.
Exposure to Cr(III) has not been found to cause any liver effects in workers
employed in two factories that produced Cr(III) oxide or Cr(III) sulfate
[Korallus, Ehrlicher et al. 1974b].
Gastro- In a study of 97 workers from a chrome plant exposed to a mixture of
intestinal insoluble chromite ore containing Cr(III) and soluble Cr(VI) as sodium
Effects chromate and dichromate, gastrointestinal radiography revealed that 10 of
the workers had ulcer formation, and of these, six had hypertrophic gastritis.
Nearly all of the workers breathed through the mouth while at work and
swallowed the chromate dust, thereby directly exposing the gastrointestinal
mucosa [Mancuso 1951]. Most of the previous studies reporting
gastrointestinal effects, however, did not compare the workers with
appropriate controls.
Page 34 of 67
Cases of gastrointestinal effects after oral exposure to Cr(VI) compounds

have also been reported. In one study, a 14-year-old boy who died after
ingesting 7.5 mg Cr(VI)/kg as potassium dichromate experienced abdominal
pain and vomiting before death. Autopsy revealed gastrointestinal ulceration
[Kaufman, DiNicola et al. 1970]. In another study, a 44-year-old man died of
gastrointestinal hemorrhage after ingesting 4.1 mg Cr(VI)/kg as chromic acid
solution [Saryan and Reedy 1988].
Cardiovascular Case reports of humans who died after ingesting Cr(VI) compounds have
Effects described cardiovascular effects as part of the sequelae leading to death.
A 22-month-old boy who ingested an unknown amount of sodium dichromate

died of cardiopulmonary arrest. Autopsy revealed early hypoxic changes in
the myocardium [Ellis, Brouhard et al. 1982]. A 35-year-old woman
developed cardiovascular collapse and shock within a few hours following
ingestion of 50 mL chromic acid [Loubieres, de Lassence et al. 1999]. A
woman ingested 400 ml of leather tanning solution containing 48 grams of
basic chromium sulphate (CrOHSO4). The patient died of cardiogenic shock,
complicated by pancreatitis and gut mucosal necrosis and hemorrhage [van
Heerden, Jenkins et al. 1994]. A 33-year-old male developed hypotension,
ventricular arrhythmias, severe respiratory distress, and metabolic acidosis
after ingesting an unknown amount of a liquid wood preservative containing
chromium trioxide, arsenic pentoxide, and copper oxide [Hay, Derazon et al.
2000].
Hematological Cases of hematological effects have been reported in humans after the
Effects ingestion of lethal or sublethal doses of Cr(VI) compounds. In a case of an
18-year-old woman who ingested a few grams of potassium dichromate,
decreased hemoglobin content and hematocrit, and increased total white
blood cell counts, reticulocyte counts, and plasma hemoglobin were found 4
days after ingestion. These effects were indicative of intravascular hemolysis
[Sharma, Singhal et al. 1978].
Laboratory analysis of a 35-year-old woman, who died 12 hours after

ingesting 50 ml of pure chromic acid [25 g Cr(VI)], revealed anemia
(hemoglobin 56 g/L, hematocrit 17 percent) and thrombocytopenia
[Loubieres, de Lassence et al. 1999].
Reproductive One study showed wives of stainless steel welders were at higher risk of
and spontaneous abortions [Bonde, Olsen et al. 1992]. The more recent study
Developmental [Hjollund, Bonde et al. 1995], however, did not corroborate those findings.
Effects No data were located regarding chromium in adverse human developmental
effects.
Several animal studies provide evidence that Cr(VI), after oral exposure, is a
developmental toxicant in rats and mice [ATSDR 2000]. Adverse
developmental effects in animals include greater incidence of post-
implantation loss, decreased fetal body weight, reduced ossification, and
decreased number of live fetuses.
Genotoxic and The mechanism of chromium-induced genotoxicity is not fully understood.
Mutagenic
Effects In one experiment, Cr(VI) plus glutathione induced DNA damage in vitro,
whereas Cr(III) with or without glutathione did not. Chromium seems to
exert its genetic effects by binding directly to DNA. It can produce stable
DNA-chromium complexes, DNA strand breaks, DNA-DNA cross links, and
Page 35 of 67
DNA-protein cross links. The active species for DNA binding seems to be the
trivalent form [De Flora, Bagnasco et al. 1990; Cohen, Kargacin et al. 1993;
Meditext 2005].
A recent clinical study reported strong DNA oxidative damage from the
urinary samples of the patient who ingested 2 to 3 grams of potassium
dichromate in a suicide attempt [Hantson, Van Caenegem et al. 2005].
Another study showed an involvement of the oxidative damage pathway in
the mechanism of toxicity of chromium in occupationally exposed individuals
[Goulart, Batoreu et al. 2005].
Cr(VI) compounds are clearly mutagenic in the majority of experimental

situations [De Flora, Bagnasco et al. 1990; Cohen, Kargacin et al. 1993]. It
has caused chromosome aberrations in mammalian cells and has been
associated with increased frequencies of chromosome aberrations in
lymphocytes from chromate production workers. Increases in sister
chromatid exchanges were seen in lymphocytes from workers exposed to
chromium, cobalt, and nickel dusts [WHO 1990; Meditext 2005].
Other Effects In a chrome plating plant where poor exhaust resulted in excessively high
concentration of chromium trioxide fumes, workers experienced symptoms of
dizziness, headache, and weakness when working over the chromate tanks
[Lieberman 1941].
Erosion and discoloration of the teeth may occur with Cr(VI) compounds
exposure. In addition, papillomas of the oral cavity and larynx have been
reported in workers exposed to high air concentration of Cr(VI) [Hathaway,
Proctor et al. 1996].
Severe corneal injury may result from ocular contact with solid or
concentrated solutions of chromic acid and other Cr(VI) compound [Grant
1993].
Key Points • When inhaled, chromium compounds are respiratory tract irritants
and can cause pulmonary sensitization.
• Chronic inhalation of Cr(VI) compounds increases the risk of lung,
nasal, and sinus cancer.
• Severe dermatitis and usually painless skin ulcers can result from
contact with Cr(VI) compounds.
• Chromium compounds can be sensitizers as well as irritants.
• DHHS, EPA, WHO, and IARC have all recognized Cr(VI) as a human
carcinogen.
• Occupational exposure to Cr(VI) compounds in a number of industries
has been associated with increased risk of respiratory system
cancers.
• Latency for Cr(VI)-induced lung cancer can be greater than 20 years.
• Some studies indicated that reversible renal tubular damage can
occur after low-dose, chronic Cr(VI) exposure.
• Occupational exposure to Cr(III) does not appear to be associated
with renal effects.
• Cr(VI) compounds can cause mild to severe liver abnormalities.
• Some Cr(VI) compounds, such as potassium dichromate and
chromium trioxide, are caustic and irritating to gastrointestinal
mucosal tissue.
Page 36 of 67
• Ingestion of a lethal dose of chromate can result in cardiovascular

collapse.
• Oral exposure to Cr(VI) compounds may result in hematological
toxicity.
• Potential reproductive effects of chromium in humans have not been
adequately investigated.
• Data indicate that Cr(VI) compounds are teratogenic in animals.
• Cr(VI) compounds induced DNA damage, gene mutation, sister
chromatid exchange, chromosomal aberrations in a number of
targets, including animal cells in vivo and animal and human cells in
vitro.
Progress Check 7. Which of the following is a major target of inhalation exposure to

chromium compounds?
A. Gastrointestinal tract.
B. Respiratory tract.
C. Cardiovascular system.
D. Central nervous system.
To review relevant content, see “Respiratory Effects” in this section.
8. Which of the following health effects from exposure to chromium is often

reportedly seen in the general public?
A. Its carcinogenicity.
B. Its irritant effect.
C. Its skin sensitizing effect.
D. Its hematopoietic toxicity.
To review relevant content, see “Skin Effects” in this section.
9. Which of following statements is NOT correct?
A. Latency for Cr(VI)-induced lung cancer can be greater than 20 years.

B. No cancers, other than lung cancer, are associated with occupational
chromium exposure.
C. No evidence exists to indicate that Cr(III) can cause cancer in animals
or humans.
D. Epidemiological evidence strongly points to Cr(VI) as the agent in
carcinogenesis. Solubility and other characteristics of chromium
compounds and Cr(VI) dust particles may be important in
determining cancer risk.
To review relevant content, see “Carcinogenic Effects” in this section.
Page 37 of 67
Answers 7. The correct answer is B. Respiratory tract is a major target of

inhalation exposure to chromium compounds.
8. The correct answer is C. Chromium is one of the most common skin

sensitizers and often causes skin sensitizing effect in the general
public. A possible source of chromium exposure is waste dumps for
chromate-producing plants causing local air or water pollution.
9. The correct answer and false statement is B. Lung cancer is not the
only cancer caused by Cr(VI) compounds. In addition to the lung
cancer, a number of epidemiological studies of workers in chromate
industries also showed significantly increased risk for nasal and sinus
cancers.
Page 38 of 67
Clinical Assessment - History, Signs and Symptoms

Objectives
• describe characteristic clinical presentations of patients with acute and
chronic chromium exposure.
Introduction Characteristic clinical presentations of patients with Cr(VI) compound

exposure include
• sinusitis, nasal septum perforation,

• allergic and irritant dermatitis, skin ulcers,
• respiratory irritation, bronchitis, asthma, and
• lung cancer [Lewis 2004].
Patient History Often, no clear diagnostic clues exist in chromium-exposed patients. A

and Physical thorough history is therefore critical in evaluating a potentially exposed
Examination person.
The patient’s recent activities are important. Occupation, location of

residence and workplace in relation to industrial facilities or hazardous waste
sites, and source of drinking water supply should be investigated.
In patients with known chronic chromium exposure, the physical examination

should include evaluation of the respiratory system, kidneys, liver, and skin.
Signs and Acute Exposure
Symptoms
Acute poisoning is likely to occur through the oral route, whereas chronic
poisoning is mainly from inhalation or skin contact [Meditext 2005].
Severe exposures to Cr(VI) compounds are usually accidental or intentional

(suicide), and are rarely occupational or environmental.
Oral intake of Cr(VI) compound may cause
• intense gastrointestinal irritation or ulceration and corrosion,

• epigastric pain,
• nausea,
• vomiting,
• diarrhea,
• vertigo,
• fever,
• muscle cramps,
• hemorrhagic diathesis,
• toxic nephritis,
• renal failure,
• intravascular hemolysis,
• circulatory collapse,
• liver damage,
• acute multisystem organ failure, and
• coma, and even death, depending on the dose [Hay, Derazon et
al. 2000; Lewis 2004; Meditext 2005].
Page 39 of 67
Acute Cr(VI) poisonings are often fatal regardless of the therapy used. The
average oral lethal dose of Cr(VI) in humans is 1-3 grams (Meditext 2005).
Systemic symptoms and death have occurred after external burns, with a
delay of onset of gastrointestinal symptoms of hours and days. Burns initially
resemble first and second degree burns, but extend to subcutaneous tissue
within a couple of days [Schiffl, Weidmann et al. 1982; Meditext 2005].
Signs and Chronic Exposure
Symptoms
Repeated skin contact with chromium dusts can lead to incapacitating
eczematous dermatitis with edema. Chromate dusts can also produce
irritation of the conjunctiva and mucous membranes, nasal ulcers and
perforations, keratitis, gingivitis, and periodontitis [Cohen and Costa 1998].
When a solution of chromate contacts the skin, it can produce penetrating

lesions known as chrome holes or chrome ulcers, particularly in areas where
a break in the epidermis is already present. These commonly occur on the
fingers, knuckles, and forearms. The characteristic chrome sore begins as a
papule, forming an ulcer with raised hard edges. Ulcers can penetrate deep
into soft tissue or become the sites of secondary infection, but are not known
to lead to malignancy. [Geller 2001; Lewis 2004; Meditext 2005].
Lung cancer is the most serious long-term effect [Cohen and Costa 1998;
Lewis 2004; Meditext 2005]. Apart from the carcinogenic potential,
prolonged exposure can result in bronchitis, rhinitis, or sinusitis or the
formation of nasal mucosal polyps. Besides the lungs and intestinal tract, the
liver and kidney are often target organs for chromate toxicity [Rom 2007].
Reports on adverse effects from low-level environmental exposures in human

populations are limited. Hudson County, NJ, was a major center for the
processing of chromium ore. A study using immune-function assay described
reduced production of cytokines in individuals who were exposed to
chromate [Snyder, Udasin et al. 1996]. Long-term studies in which animals
have been exposed to low levels of chromium in food or water have
produced no harmful effects [ATSDR 2000].
Key Points • Acute poisoning is likely to occur through the oral route, whereas chronic
poisoning is mainly from inhalation or skin contact.
• Severe exposures to Cr(VI) compounds are usually accidental or
intentional (suicide), and are rarely occupational or environmental.
• In occupational settings, the most commonly reported effects of chronic
chromium exposure are contact dermatitis and irritation and ulceration of
the nasal mucosa.
• Lung cancer is a potential long-term effect of chronic Cr(VI) exposure.
• Besides the lungs and intestinal tract, the liver and kidney are often
target organs for chromate toxicity from chronic exposure.
Page 40 of 67
Progress Check 10. Which of the following is the most serious long-term effect from chronic
Cr(VI) exposure?
A. Contact dermatitis.
B. Nasal septum perforation.
C. Bronchitis.
D. Lung cancer.
To review relevant content, see “Signs and Symptoms - Chronic

Exposure” in this section.
11. Common sites for persistent ulcers (“chrome holes”) include all of the
following sites EXCEPT
A. Finger webs.
B. Back of hands.
C. Forearms.
D. Palms of hands.
To review relevant content, see “Signs and Symptoms - Chronic

Exposure” in this section
Page 41 of 67
Answers 10. The correct answer is D. Although answers A-C are characteristic
clinical findings of chronically exposed patients, lung cancer is the most
serious long-term adverse health effect.
11. The correct answer is D. Persistent ulcers (“chrome holes”) are not
found on the palm of the hands. Common sites for persistent ulcers do
include the finger webs, knuckles, back of the hands, and the
forearms.
Page 42 of 67
Clinical Assessment - Laboratory Tests

Objectives
• identify laboratory tests that can assist with diagnosis of chromium
exposure.
Introduction With excessive exposure, there will be evidence of renal and hepatic
damage. Proteinuria and hematuria precede anuria and uremia.
A reduction in the FEV1: FVC ratio on spirometry may be seen after acute
irritant exposure or in workers with chromium-induced asthma.
Skin allergy can be confirmed by patch testing.
Persistent cough, hemoptysis, or a mass lesion on chest radiograph in a

chromium worker should prompt a thorough evaluation for possible lung
cancer [Lewis 2004].
Initial Lab The following tests should be considered in the evaluation of Cr(VI) exposure
Exams [HSDB 2000]
• complete blood count,

• liver function tests (aspartate aminotransferase (AST) or serum
glutamic-oxaloacetic transaminase (SGOT), ALT or serum glutamic-
pyruvic transaminase (SGPT), and bilirubin),
• blood urea nitrogen (BUN) and creatinine, and
• urinalysis.
Specialized When obtaining biologic specimens for chromium analysis, care must be
Tests taken to avoid sample contamination and chromium loss during collection,
transportation, and storage. For example, use of stainless steel utensils to
collect tissue samples might raise tissue chromium levels, as will stainless
steel grinding and homogenizing equipment. Some plastic containers contain
significant amounts of leachable chromium; therefore, specially prepared
acid-washed containers should be obtained from the laboratory.
Considerable care also must be taken in the analysis to minimize chromium

volatilization during sample washing [EPA 1984a].
Blood Or Serum Chromium Levels

Several methods are available for the analysis of chromium in different
biological media [ATSDR 2000]. For example, Cr(VI) and complexes of
Cr(III) can be rapidly determined in plasma and other biological specimens
via a high performance anion-exchange liquid chromatograph technique
[Suzuki 1987].
Blood distribution of chromium appears to be divided evenly between plasma

and erythrocytes. In the absence of known exposure, whole blood chromium
concentrations are in the range of 2.0 μg/100 mL to 3.0 μg/100 mL; lower
levels occur in rural areas, and higher levels occur in large urban centers.
Page 43 of 67
As we have discussed in the previous section on the biologic fate of

chromium, Cr(VI) enters red blood cells, but Cr(III) does not. Therefore, it is
possible to distinguish sources and types of exposure (Cr(VI) versus other
forms of Cr) by measuring RBC versus serum Cr. This can be especially
helpful if urine Cr levels are elevated and one wants to know if this indicates
a toxic (e.g., Cr[VI]) exposure or an essentially benign (e.g., Cr[III])
exposure.
Values above background levels are considered potentially toxic, but levels
have not been correlated with specific physiologic effects. Chromium rapidly
clears from the blood, and measurements relate only to recent exposure.
Urinary Chromium Levels
Wide individual variation in metabolism and rapid depletion of body burden

limit the value of urinary chromium monitoring.
Urinary chromium excretion reflects absorption over the previous 1 or 2 days

only.
In occupational settings, a urinary chromium concentration of 40 μg/L to 50

μg/L, immediately after a work shift reflects exposure to air levels of 50
μg/m³ of soluble Cr(VI) compounds, a concentration associated with nasal
perforations in some studies. If sufficient time has elapsed for urinary
clearance, a negative bio-monitoring result can occur even with injurious
past exposure.
Assuming no source of excessive exposure, urinary chromium values are

typically less than 10 μg/L for a 24-hour period [ATSDR 2000].
Urinary Β2-Microglobulins Levels
Urinary β2-microglobulins were significantly higher in chromeplaters exposed

to Cr(VI) than in unexposed controls [Lindberg and Vesterberg 1983].
Hair or nail analysis is of little use in evaluating an individual patient because

it is impossible to distinguish chromium bound within the hair during protein
synthesis from chromium deposited on the hair from dust, water, or other
external sources. Populations with no known chromium exposure reportedly
have hair levels ranging from 50 parts per million (ppm) to 100 ppm
chromium.
The presence of chromium and chromium complexes in biologic complexes

can be determined using chromatographic and colorimetric techniques; patch
testing and lymphocyte proliferation testing have been used to determine
chromium sensitivity [ATSDR 2000; Meditext 2005].
Other If the patient has had possible Cr(VI) inhalation exposure, a chest
Measurements radiograph and pulmonary function test should be included [Lewis 2004;
Meditext 2005].
Page 44 of 67
Key Points • Chromium can be measured in blood and urine; hair or nail analysis
has no clinical value.
• Urinary chromium excretion is a useful index of exposure in
occupational settings. However, it reflects exposure over the previous
1 or 2 days only.
Progress Check 12. To confirm chromium exposure, which of the following measurements is
the most reliable?
A. Chromium in blood and urine.

B. Pulmonary lesion shown on radiograph.
C. Elevated values of renal and liver function tests.
D. Elevated values of routine laboratory tests.
To review relevant content, see “Key Points” in this section.
Page 45 of 67
Answers 12. The correct answer is A, chromium in the blood and urine. If the cause
of patient symptoms is questionable, direct biologic testing, such as
measuring the chromium level in blood, or urine, may be warranted to
confirm chromium exposure. Keep in mind, however, that chromium
rapidly clears from the blood, and measurements relate only to recent
exposure. Therefore, for patients with a known history of chronic
chromium exposure, a thorough evaluation including a complete
exposure history, a complete blood count, chest x-ray, FVC and FEV1,
urinalysis, kidney function tests, liver function tests, and
dermatological examination would be appropriate for approaching an
accurate diagnosis.
Page 46 of 67
How Should Patients Exposed to Chromium Be Treated and Managed?

Objectives
• describe the principal treatment strategy for managing chromium
poisoning.
Introduction No matter what route of exposure, the initial approach to an affected

individual includes a brief assessment of clinical status followed by support of
basic cardiopulmonary functions.
Once the airway has been stabilized and cardiopulmonary support has been
instituted as indicated, further measures can be considered [Geller 2001].
Acute Exposure No proven antidote is available for chromium poisoning. Acute poisoning is
often fatal regardless of therapy. Treatment in cases of acute high-level
chromium exposure is usually supportive and symptomatic.
Fluid and electrolyte balance is critical.
Affected patients should be monitored carefully for evidence of
• gastrointestinal bleeding,
• hemolysis,
• coagulopathy,
• seizures, and
• pulmonary dysfunction [Geller 2001].
Appropriate supportive measures may include ventilatory support,

cardiovascular support, and renal and hepatic function monitoring.
When renal function is compromised, maintenance of adequate urine flow is

important. Progression to anuria is associated with poor prognosis [Meditext
2005].
Induction of vomiting is contraindicated, owing to the potential corrosive
effects of the chromium compounds and the potential for rapid deterioration
of the patient [Geller 2001; Meditext 2005].
Gastric lavage with magnesium hydroxide or another antacid might be useful

in cases of chromium ingestion.
The efficacy of activated charcoal has not been proven.
Orally administered ascorbic acid was found to be protective in experimental

animals and was reported beneficial in at least one patient after chromium
ingestion; however, no clinical trials have been conducted to confirm the
efficacy of this treatment [Bradberry and Vale 1999].
Exchange transfusion was effective in reducing blood chromium levels 67%

in one case of chromium poisoning, using 10.9 L of blood [Kelly, Ackrill et al.
1982]. Existing evidence does not allow the conclusion that exchange
transfusion generally should be employed, however [Geller 2001].
Page 47 of 67
Hemodialysis and charcoal hemoperfusion do not substantially enhance

chromium removal from the body if renal function remains normal [Ellis,
Brouhard et al. 1982]. However, if renal failure ensues, hemodialysis may be
necessary for management of the renal failure itself [Schiffl, Weidmann et al.
1982; Geller 2001].
Chelation with ethylenediaminetetraacetic acid (EDTA) does not seem to be

of clinical benefit [Geller 2001].
If the eyes and skin are directly exposed, flush with copious amounts of
water.
Several case reports suggest that topical ascorbic acid is effective in the
management of chromium dermatitis but this has not been confirmed in
controlled clinical trials [Bradberry and Vale 1999]. The ulcers heal in several
weeks without specific treatment.
Ethylenediaminetetraacetic acid (EDTA) ointment 10% might facilitate

removal of chromate scabs [Geller 2001; Lewis 2004].
Weeping dermatitis can be treated with 1% aluminum acetate wet dressings,

and chrome ulcers can be treated with topical ascorbic acid [Geller 2001;
Meditext 2005].
Chronic In most patients with chronic low-dose exposure, no specific treatment is
Exposure needed.
The mainstay of management is removing the patient from further exposure

and relying on the urinary and fecal clearance of the body burden.
Although normal urinary excretion is quite rapid, forced diuresis has been
used.
Except in the lungs, only small amounts of chromium are retained several
weeks after exposure has ceased.
Dermatitis, liver and renal injury will not progress after removal from
exposure, and, in most cases, the patient will recover.
If the exposure has been to high levels or lengthy, the increased risk of lung
cancer should be discussed with the patient.
Although no reliable tests are currently available to screen patients for lung
cancer, the physician can provide advice and patient education regarding
smoking cessation, avoiding or minimizing exposure to other known
pulmonary carcinogens, and general preventive health measures.
Annual chest radiographs might be advisable in carefully selected cases

[HSDB 2000; Meditext 2005].
Page 48 of 67
Key Points • No proven antidote is available for chromium poisoning.

• Treatment in cases of acute high-level chromium exposure is usually
supportive and symptomatic.
• Treatment consists of removal of the patient from further chromium
exposure, reliance on the body’s naturally rapid clearance of the metal
and symptomatic management.
• The physician can provide advice and patient education regarding
smoking cessation, how to avoid or minimize exposure to other known
pulmonary carcinogens, and general preventive health measures.
Progress Check 13. Which of following measures is incorrect when managing patients with
acute chromium poisoning:
A. Ventilatory and cardiovascular support.

B. Maintenance of adequate urine.
C. Induction of vomiting.
D. Hepatic function monitoring.
To review relevant content, see “Acute Exposure” in this section.
14. Which of the following statements is incorrect?
A. Except in the lungs, only small amounts of chromium are retained

several weeks after exposure has ceased.
B. Dermatitis, liver, and renal injury will not progress after removal from
exposure.
C. If the exposure has been lengthy (i.e., 2 years to 3 years), the
increased risk of lung cancer should be discussed with the patient.
D. The mainstay of management for chronic exposure is relying on
chromium clearance techniques, such as hemodialysis, exchange
transfusions, or chelating agents such as dimercaprol or EDTA.
To review relevant content, see “Chronic Exposure” in this section.
Page 49 of 67
Answers 13. The correct answer is C. Induction of vomiting is contraindicated, due

to the potential corrosive effects of the chromium compounds and the
potential for rapid deterioration of the patient. Treatment in cases of
acute, high-level chromium exposure is usually supportive and
symptomatic.
14. The correct answer is D. Hemodialysis, exchange transfusions, or

chelating agents such as dimercaprol or EDTA have not been shown to
be effective in the treatment of human poisoning. The mainstay of
management is removing the patient from further exposure and
relying on the urinary and fecal clearance of the body burden.
Page 50 of 67
What Instructions Should Be Given to Patients Exposed to Chromium?

Objectives
• describe patient self care, and
• describe clinical follow-up.
Introduction Cr(VI) compounds are widely used in the chemical industry as ingredients
and catalysts in pigments, metal plating and chemical synthesis. Cr(VI) can
also be produced when welding on stainless steel or Cr(VI)-painted surfaces.
The major health effects associated with exposure to Cr(VI) include lung
cancer, nasal septum ulcerations and perforations, skin ulcerations, and
allergic and irritant contact dermatitis.
All patients exposed to chromium need some basic guidance on
• self care, so they can minimize further risks and avoid complications to
the extent possible and
• clinical follow up, so they understand when and why to return for
further medical attention.
Self Care Effective steps patients should be advised to take to prevent and eliminate
exposure.
• Wear proper personal protective equipment such as respiratory

protection, protective clothing, eye protection, and gloves.
• Maintain a clean work area free of dust.
• Shower and change clothes immediately on completion of work.
• Leave or dispose of contaminated clothing at the work site.
• Do not track dust from the work area to the rest of the home.
• Do not smoke, eat, or drink in the work area.
• Wash hands well before eating, drinking, or smoking.
• Heed employer provided patient and worker education.
• If a smoker, stop smoking.
Clinical Follow- Patients should be advised to call if they develop any of the following
Up symptoms:
• symptoms of kidney dysfunction such as lower extremity swelling,

reduced urine volume, changes in color of urine, etc.,
• dyspnea, cough, wheezing,
• nausea, vomiting, diarrhea,
• yellowing of the teeth,
• altered sense of smell, and
• if you suspect you have been exposed.
Page 51 of 67
Key Points • Patients should be advised to avoid exposures and conditions that might
further increase their risk of disease or worsen their existing condition.
• Patients should contact their physician if they develop respiratory or
gastrointestinal problems or other health changes.
Progress Check 15. Patients who have been exposed to chromium should
A. Seek clinical evaluation and treatment without delay.

B. Learn how to avoid further exposure.
C. Know when to call their doctor.
To review relevant content, see “Self Care” and “Clinical Follow-up” in

this section.
Page 52 of 67
Answers 15. The correct answer is D, all of the above. Patients who have been
exposed to chromium should seek clinical evaluation and treatment
without delay, learn how to avoid further exposure, and know when to
call their primary care physician.
Page 53 of 67
Sources of Additional Information
Chromium Please refer to the following Web resources for more information on the
Specific adverse effects of chromium, the treatment of chromium -associated
Information diseases, and management of persons exposed to chromium.
• Agency for Toxic Substances and Disease Registry

(www.atsdr.cdc.gov)
o For chemical, emergency situations
CDC Emergency Response: 770-488-7100 and request

the ATSDR Duty Officer
o For chemical, non- emergency situations
CDC-INFO (www.bt.cdc.gov/coca/800cdcinfo.asp)
800-CDC-INFO (800-232-4636) TTY 888-232-6348 - 24
Hours/Day
E-mail: [email protected]
PLEASE NOTE
ATSDR cannot respond to questions about individual medical
cases, provide second opinions or make specific
recommendations regarding therapy. Those issues should be
addressed directly with your health care provider.
o Toxicological Profile for Chromium

www.atsdr.cdc.gov/toxprofiles/tp7.pdf)
o TOXFAQs for Chromium www.atsdr.cdc.gov/tfacts7.html, or in
Spanish, www.atsdr.cdc.gov/es/toxfaqs/es_tfacts7.html
• National Institute of Safety and Health (NIOSH) Safety and Health

Topic - Chromium - www.cdc.gov/niosh/topics/chromium/
• National Institute of Safety and Health (NIOSH) Safety and Health
Topic - Hexavalent Chromium www.cdc.gov/niosh/topics/hexchrom/
• OSHA Chemical Sampling Information - Chromium(VI) (Hexavalent
Chromium)
www.osha.gov/dts/chemicalsampling/data/CH_228697.html
• U.S. Environmental Protection Agency - Technology Transfer Network
- Air Toxics Web Site - Chromium Compounds
www.epa.gov/ttn/atw/hlthef/chromium.html
Clinical • American College of Occupational and Environmental Medicine

Resources (ACOEM) (www.acoem.org)
o ACOEM is the nation's largest medical society dedicated to

promoting the health of workers through preventive medicine,
clinical care, research, and education.
o Its members are a dynamic group of physicians encompassing
specialists in a variety of medical practices is united via the
Page 54 of 67
College to develop positions and policies on vital issues relevant

to the practice of preventive medicine both within and outside of
the workplace.
• American College of Medical Toxicologists (ACMT) (www.acmt.net)
o ACMT is a professional, nonprofit association of physicians with

recognized expertise in medical toxicology.
o The College is dedicated to advancing the science and practice of
medical toxicology through a variety of activities.
• Association of Occupational and Environmental Clinics www.aoec.org
o The Association of Occupational and Environmental Clinics (AOEC)

is a network of more than 60 clinics and more than 250
individuals committed to improving the practice of occupational
and environmental medicine through information sharing and
collaborative research.
• Pediatric Environmental Health Specialty Units (PEHSUs)

www.aoec.org/PEHSU.htm
o Each PEHSU is based at an academic center and is a collaboration

between the pediatric clinic and the (AOEC) occupational and
environmental clinic at each site.
o The PEHSU's have been developed to provide education and
consultation for health professionals, public health professionals
and others about the topic of children's environmental health.
o The PEHSU staff is available for consultation about potential
pediatric environmental health concerns affecting both the child
and the family. Health care professionals may contact their
regional PEHSU site for clinical advice.
• Poison Control Center
o The American Association of Poison Control Centers may be

contacted for questions about poisons and poisonings. The web
site provides information about poison centers and poison
prevention. AAPC does not provide information about treatment
or diagnosis of poisoning or research information for student
papers.
o American Association of Poison Control Centers (1-800-222-1222
or www.aapcc.org).
Page 55 of 67
General Please refer to the following Web resources for general information on
Environmental environmental health.
Health
Information • Agency for Toxic Substances and Disease Registry
(www.cdc.gov/atsdr)
o To view the complete library of CSEMs

(www.atsdr.cdc.gov/csem/).
o Taking an Exposure History CSEM
(www.atsdr.cdc.gov/csem/exphistory/)
• Centers for Disease Control and Prevention (CDC)(www.cdc.gov)
o CDC works to protect public health and the safety of people, by

providing information to enhance health decisions, and promotes
health through partnerships with state health departments and
other organizations.
o The CDC focuses national attention on developing and applying
disease prevention and control (especially infectious diseases),
environmental health, occupational safety and health, health
promotion, prevention and education activities designed to
improve the health of the people of the United States.
• National Center for Environmental Health (NCEH)

(www.cdc.gov/nceh/)
o NCEH works to prevent illness, disability, and death from
interactions between people and the environment. It is especially
committed to safeguarding the health of populations that are
particularly vulnerable to certain environmental hazards -
children, the elderly, and people with disabilities.
o NCEH seeks to achieve its mission through science, service, and
leadership.
• National Institute of Health (NIH) (www.nih.gov)
o A part of the U.S. Department of Health and Human Services, NIH

is the primary Federal agency for conducting and supporting
medical research.
• National Institute of Occupational Safety and Health (NIOSH)

(www.cdc.gov/niosh/)
o NIOSH is in the U.S. Department of Health and Human Services

and is an agency established to help assure safe and healthful
working conditions for working men and women by providing
research, information, education, and training in the field of
occupational safety and health.
Page 56 of 67
• Association of Occupational and Environmental Clinics

(www.aoec.org)
o The Association of Occupational and Environmental Clinics (AOEC)

is a network of more than 60 clinics and more than 250
individuals committed to improving the practice of occupational
and environmental medicine through information sharing and
collaborative research.
ATSDR Division The Division of Regional Operations fulfills the Agency's directives at
of Regional the regional level by staffing an ATSDR Regional Office within each of
Operations the 10 EPA Regional Offices.
The regional representatives are essential liaisons with all

NCEH/ATSDR divisions and offices and facilitate the implementation of
ATSDR specific programs in the regions. Through the working
relationships they have established with EPA, other federal and state
agencies, individual citizens, and community groups, regional
representatives are able to maintain current and historic knowledge of
the hazardous sites and issues in their regions. This information
enables ATSDR to address regional issues with appropriate sensitivity
and make informed decisions.
ATSDR's Regional Offices, along with the states and territories that
they cover as well as contact information, can be found at:
www.atsdr.cdc.gov/DRO/dro_contact.html
Page 57 of 67
Posttest
Introduction ATSDR seeks feedback on this course so we can asses its usefulness and
effectiveness. We ask you to complete the assessment questionnaire online
for this purpose.
In addition, if you complete the assessment and posttest online, you can
receive continuing education credits as follows.
Accrediting
Credits Offered
Organization
Accreditation The Centers for Disease Control and Prevention is accredited by the
Council for Accreditation Council for Continuing Medical Education (ACCME) to provide
Continuing continuing medical education for physicians. The Centers for Disease Control
Medical Education and Prevention designates this educational activity for a maximum of 2.0
(ACCME) AMA PRA Category 1 Credits. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
American Nurses The Centers for Disease Control and Prevention is accredited as a provider of
Credentialing Continuing Nursing Education by the American Nurses Credentialing Center's
Center (ANCC), Commission on Accreditation. This activity provides 2.0 contact hours.
Commission on
Accreditation
National The Centers for Disease Control and Prevention is a designated provider of
Commission for continuing education contact hours (CECH) in health education by the
Health Education National Commission for Health Education Credentialing, Inc. This program is
Credentialing, a designated event for the CHES to receive 2.0 Category I contact hours in
Inc. (NCHEC) health education, CDC provider number GA0082.
International The CDC has been approved as an Authorized Provider by the International
Association for Association for Continuing Education and Training (IACET), 1760 Old
Continuing Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by
Education and IACET to offer 0.2 CEU's for this program.
Training (IACET)
Disclaimer In compliance with continuing education requirements, all presenters must

disclose any financial or other relationships with the manufacturers of
commercial products, suppliers of commercial services, or commercial
supporters as well as any use of unlabeled product(s) or product(s) under
investigational use.
CDC/ATSDR, our planners, and the presenters for this seminar do not have
financial or other relationships with the manufacturers of commercial products,
suppliers of commercial services or commercial supporters. This presentation
does not involve the unlabeled use of a product or product under
investigational use.
Page 58 of 67
Instructions To complete the assessment and posttest, go to www2.cdc.gov/atsdrce/ and

follow the instructions on that page.
You can immediately print your continuing education certificate from your
personal transcript online. No fees are charged.
Posttest 1. Which of the following statements is NOT true?
A. Chromium is excreted in urine and bile as Cr(III).

B. Cr(III) is generally more toxic than Cr(IV).
C. Cr(VI) is absorbed more quickly than Cr(III).
D. Cr(VI) is carcinogenic when inhaled.
2. Which of the following statements is correct?
A. Naturally occurring chromium is usually present as hexavalent Cr(VI).

B. Cr(III) and Cr(VI) are released to the environment primarily from
stationary point sources resulting from human activities.
C. Cr(VI) in the air does not undergo any reaction.
D. Tobacco smoke is a source of chromium intake.
3. Which of the following statements is incorrect?
A. Due to the actions of gastric acid and other components within the
gastrointestinal tract, most of ingested Cr(VI) dosage is converted to
Cr(III)
B. Cr(VI) is reduced to Cr(III) in the lower respiratory tract.
C. Absorption of Cr(VI) compounds can not occur through intact skin.
D. The general population is exposed most often by ingestion through
chromium content in soil, food, and water.
4. EPA’s MCL for chromium in drinking water is which of the following?
A. 50 g/L.
B. 100 g/L.
C. 500 g/L.
5. Which of the following is NOT true?
A. Chromium deficiency may result in glucose intolerance.

B. Cr(VI) compounds are irritating and corrosive.
C. Cr(III) readily passes through cell membranes.
D. Chromium compounds may be skin and pulmonary sensitizers.
6. Significant chromium uptake occurs in all of the following EXCEPT
A. Lung.
B. Kidneys.
C. Muscle.
D. Liver.
Page 59 of 67
7. Dermal signs of chromium exposure may include all of the following EXCEPT
A. Penetrating, painless, and persistent ulcers.

B. Papule-like lesions.
C. Dermatitis with eczema and edema.
D. Erythema nodosum.
8. Effects of chronic chromium exposure may include all of the following

EXCEPT
A. Pancreatitis.
B. Nasal mucosal irritation.
C. Chromium-induced asthma.
D. Lung cancer.
9. Because Cr(VI) is a powerful oxidizing agent, it does all of the following

EXCEPT
A. Causes gastrointestinal hemorrhage as a result of ingestion.

B. Causes skin necrosis on dermal contact.
C. Appears to be much more toxic systemically than Cr(III) compounds,
given similar amounts and solubilities.
D. Is eliminated in the urine.
10. Which of the following tests is of little use in evaluating a chromium-exposed

individual?
A. Urinary β2-microglobulins level.

B. Urinary chromium level.
C. Chromium level in the hair.
D. Chest x-ray.
11. Treatment recommendations for patients with chronic chromium poisoning

may include all of the following EXCEPT
A. Prolonged chelation therapy with dimercaprol.

B. Cessation of further exposure.
C. Surveillance for lung cancer.
D. Topical ascorbic acid treatment for chrome ulcers.
12. Patients who have been exposed to chromium should contact their physician
if they develop all of the following EXCEPT
A. Respiratory problems.
B. Yellowing of teeth.
C. Altered sense of smell.
D. Difficulty sleeping.
Page 60 of 67
Relevant
To review content relevant to the posttest questions, see
Content
Question Location of Relevant Content
1 What is chromium?
2 Where is chromium found?
3 What are the routes of exposure to chromium?
4 What are the standards and regulations for chromium exposure?
5 What is the biologic fate of chromium in the body?
6 What is the biologic fate of chromium in the body?
7 What are the physiologic effects of chromium?
8 What are the physiologic effects of chromium?
9 Clinical assessment - history, signs and symptoms
10 Clinical assessment - laboratory tests
11 How should patients exposed to chromium be treated and managed?
12 What instructions should be given to patients?
Page 61 of 67
Literature Cited
References • Adams, R. M. (1990). "In: Occupational Skin Disease, 2nd ed.,

Adams, RM, ed." Philadelphia: W.B. Saunders, pp. 26-31.
• Agency for Toxic Substances and Disease Registry (2000).
"Toxicological Profile for Chromium."
http://www.atsdr.cdc.gov/toprofiles/tp7.html.
• Aitio, A., J. Jarvisalo, et al. (1984). "Urinary excretion of chromium as
an indicator of exposure to trivalent chromium sulphate in leather
tanning." International Archives of Occupational & Environmental
Health 54(3): 241-9.
• Axelsson, G., R. Rylander, et al. (1980). "Mortality and incidence of
tumours among ferrochromium workers." British Journal of Industrial
Medicine 37(2): 121-7.
• Baetjer, A. M. (1950). Pulmonary carcinoma in chromate workers. 1.
A review of the literature and report of cases, A. M. A. Archives of
Industrial Hygiene & Occupational Medicine. 2(5):487-504, 1950 Nov.
• Baranowska-Dutkiewicz, B. (1981). "Absorption of hexavalent
chromium by skin in man." Archives of Toxicology 47(1): 47-50.
• Bonde, J. P., J. H. Olsen, et al. (1992). "Adverse pregnancy outcome
and childhood malignancy with reference to paternal welding
exposure." Scandinavian Journal of Work, Environment & Health
18(3): 169-77.
• Bradberry, S. M. and J. A. Vale (1999). "Therapeutic review: is
ascorbic acid of value in chromium poisoning and chromium
dermatitis?" Journal of Toxicology - Clinical Toxicology 37(2): 195-
200.
• Braver, E. R., P. Infante, et al. (1985). "An analysis of lung cancer
risk from exposure to hexavalent chromium." Teratogenesis,
Carcinogenesis, & Mutagenesis 5(5): 365-78.
• Bruynzeel, D. P., G. Hennipman, et al. (1988). "Irritant contact
dermatitis and chrome-passivated metal." Contact Dermatitis 19(3):
175-9.
• Cohen, M. D. and M. Costa (1998). In: Rom WN, ed. Environmental
and Occupational Medicine, Third Edition. Philadelphia, Lipponcott-
Raven Publishers: pp.1045-1052.
• Cohen, M. D., B. Kargacin, et al. (1993). "Mechanisms of chromium
carcinogenicity and toxicity." Critical Reviews in Toxicology 23(3):
255-81.
• Davies, J. M. (1984). "Lung cancer mortality among workers making
lead chromate and zinc chromate pigments at three English
factories." British Journal of Industrial Medicine 41(2): 158-69.
• Dayan, A. D. and A. J. Paine (2001). "Mechanisms of chromium
toxicity, carcinogenicity and allergenicity: review of the literature
from 1985 to 2000." Human & Experimental Toxicology 20(9): 439-
51.
• De Flora, S., G. S. Badolati, et al. (1987). "Circadian reduction of
chromium in the gastric environment." Mutation Research 192(3):
169-74.
• De Flora, S., M. Bagnasco, et al. (1990). "Genotoxicity of chromium
compounds. A review." Mutation Research 238(2): 99-172.
• De Mattia, G., M. C. Bravi, et al. (2004). "Impairment of cell and
plasma redox state in subjects professionally exposed to chromium."
Page 62 of 67
American Journal of Industrial Medicine 46(2): 120-5.

• Deng, J. F., A. K. Fleeger, et al. (1990). "An outbreak of chromium
ulcer in a manufacturing plant." Veterinary & Human Toxicology
32(2): 142-6.
• Donaldson, R. M., Jr. and R. F. Barreras (1966). "Intestinal absorption
of trace quantities of chromium." Journal of Laboratory & Clinical
Medicine 68(3): 484-93.
• Ellis, E. N., B. H. Brouhard, et al. (1982). "Effects of hemodialysis and
dimercaprol in acute dichromate poisoning." Journal of Toxicology -
Clinical Toxicology 19(3): 249-58.
• EPA (1984a). "Health assessment document for chromium." Research
Triangle Park, NC: Environmental Assessment and Criteria Office, U.S.
Environmental Protection Agency. EPA 600/8-83-014F.
• EPA (1998). "Toxicological Review of Trivalent Chromium. CAS No.
16065-83-1. In support of Summary Information on the Integrated
Risk Information System (IRIS). U.S. Environmental Protection
Agency, Washington, D.C."
• EPA (1999 h). "U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 141.32."
• Fagliano, J. A., J. Savrin, et al. (1997). "Community exposure and
medical screening near chromium waste sites in New Jersey."
Regulatory Toxicology & Pharmacology 26(1 Pt 2): S13-22.
• Federal Register (2006). "Occupational Exposure to Hexavalent
Chromium; Final Rule" Vol. 71, No. 39(Tuesday, February 28,
2006 / Rules and Regulations
• Foa, V., L. Riboldi, et al. (1988). "Effects derived from long-term low-
level chromium exposure in ferro-alloy metallurgy. Study of
absorption and renal function in workers." Science of the Total
Environment 71(3): 389-400.
• Franchini, I. and A. Mutti (1988). "Selected toxicological aspects of
chromium(VI) compounds." Science of the Total Environment 71(3):
379-87.
• Fregert, S. and S. Fregert (1981). "Chromium valencies and cement
dermatitis." British Journal of Dermatology 105 Suppl 21: 7-9.
• Frentzel-Beyme, R. (1983). "Lung cancer mortality of workers
employed in chromate pigment factories. A multicentric European
epidemiological study." Journal of Cancer Research & Clinical
Oncology 105(2): 183-8.
• Gad, S. C. (1989). "Acute and chronic systemic chromium
toxicity.[erratum appears in Sci Total Environ 1990 Jun;95:295]."
Science of the Total Environment 86(1-2): 149-57.
• Geller, R. (2001). "Chromium." In:Clinical Environmental Health and
Toxic Exposures. Sullivan, JB, Jr. and Krieger, GR, editors. 2nd Ed.
Lippincott Williams & Wilkins, Philadelphia, PA.
• Gibb, H. J., P. S. Lees, et al. (2000). "Clinical findings of irritation
among chromium chemical production workers." American Journal of
Industrial Medicine 38(2): 127-31.
• Gibb, H. J., P. S. Lees, et al. (2000). "Lung cancer among workers in
chromium chemical production.[see comment]." American Journal of
Industrial Medicine 38(2): 115-26.
• Goulart, M., M. C. Batoreu, et al. (2005). "Lipoperoxidation products
and thiol antioxidants in chromium exposed workers." Mutagenesis
20(5): 311-5.
Page 63 of 67
• Grant, W. M. (1993). "Toxicology of the Eye." 34th ed, Charles C

Thomas, Springfield, IL.: pp 398.
• Hantson, P., O. Van Caenegem, et al. (2005). "Hexavalent chromium
ingestion: biological markers of nephrotoxicity and genotoxicity."
Clinical Toxicology: The Official Journal of the American Academy of
Clinical Toxicology & European Association of Poisons Centres &
Clinical Toxicologists 43(2): 111-2.
• Hathaway, G. J., N. H. Proctor, et al. (1996). Chemical Hazards of
the Workplace, 4th ed, Van Nostrand Reinhold Company, New
York, NY.
• Hay, E., H. Derazon, et al. (2000). "Suicide by ingestion of a CCA
wood preservative." Journal of Emergency Medicine 19(2): 159-63.
• Hayes, R. B., A. M. Lilienfeld, et al. (1979). "Mortality in chromium
chemical production workers: a prospective study." International
Journal of Epidemiology 8(4): 365-74.
• HazDat (2000.). "Hazardous substances database." Agency for Toxic
Substances and Disease Registry (ATSDR), Atlanta, GA.
• Henderson, R. F., A. H. Rebar, et al. (1979). "Early damage indicators
in the lungs. IV. Biochemical and cytologic response of the lung to
lavage with metal salts." Toxicology & Applied Pharmacology 51(1):
129-35.
• Hjollund, N. H., J. P. Bonde, et al. (1995). "Male-mediated risk of
spontaneous abortion with reference to stainless steel welding."
Scandinavian Journal of Work, Environment & Health 21(4): 272-6.
• HSDB (2000). "Hazardous Substances Data Bank." National Library Of
Medicine. Bethesda, MD, Thomson Micromedex, CO.
• International Agency for Research on Cancer (1990). "Chromium,
Nickel and Welding." IARC Monograph on the Evaluation of
Carcinigenic Risks to Human, 49, Lyon.
• Katz, S. A. and H. Salem (1993). "The toxicology of chromium with
respect to its chemical speciation: a review." Journal of Applied
Toxicology 13(3): 217-24.
• Kaufman, D. B., W. DiNicola, et al. (1970). "Acute potassium
dichromate poisoning. Treated by peritoneal dialysis." American
Journal of Diseases of Children 119(4): 374-6.
• Kelly, W. F., P. Ackrill, et al. (1982). "Cutaneous absorption of
trivalent chromium: tissue levels and treatment by exchange
transfusion." British Journal of Industrial Medicine 39(4): 397-400.
• Kiilunen, M., H. Kivisto, et al. (1983). "Exceptional pharmacokinetics
of trivalent chromium during occupational exposure to chromium
lignosulfonate dust." Scandinavian Journal of Work, Environment &
Health 9(3): 265-71.
• Kirschbaum, B. B., F. M. Sprinkel, et al. (1981). "Proximal tubule
brush border alterations during the course of chromate nephropathy."
Toxicology & Applied Pharmacology 58(1): 19-30.
• Kolaciski, Z., P. Kostrzewski, et al. (1999). "Acute potassium
dichromate poisoning: a toxicokinetic case study." Journal of
Toxicology - Clinical Toxicology 37(6): 785-91.
• Korallus, U., H. Ehrlicher, et al. (1974b). "Trivalent chromium
compounds - results of a study in occupational medicine. Part 2.
Disease status analysis." Arb Soz Prev 9: 76-79. (German).
• Langard, S. (1983). "The carcinogenicity of chromium compounds in
man and animals." In: Burrow, C., Ed. Chromium: Metabolism and
Page 64 of 67
Toxicity. CRC Press, Inc., Boca Raton, FL, pp. 13-30.

• Langard S (1980). "A survey of respiratory symptoms and lung
function in ferrochromium and ferrosillicon workers." Int Arch Occup
Environ Health(46): 1-9.
• Langard, S. and T. Norseth (1975). "A cohort study of bronchial
carcinomas in workers producing chromate pigments." British Journal
of Industrial Medicine 32(1): 62-5.
• Langard, S. and T. Vigander (1983). "Occurrence of lung cancer in
workers producing chromium pigments." British Journal of Industrial
Medicine 40(1): 71-4.
• Lewis, R. (2004). "Occupational Exposures: Metals. In: Current
Occupational & Environmental Medicine. LaDou, J. editor. 3rd Ed."
Lange Medical Books/McGraw-Hill Companies, Inc.: pp. 439-441.
• Lieberman, H. (1941). "Chrome ulcerations of the nose and throat."
New Engl J Med(225): 132-133.
• Lindberg, E. and G. Hedenstierna (1983). "Chrome plating:
symptoms, findings in the upper airways, and effects on lung
function." Archives of Environmental Health 38(6): 367-74.
• Lindberg, E. and O. Vesterberg (1983). "Monitoring exposure to
chromic acid in chromeplating by measuring chromium in urine."
Scandinavian Journal of Work, Environment & Health 9(4): 333-40.
• Lindberg, E. and O. Vesterberg (1983). "Urinary excretion of proteins
in chromeplaters, exchromeplaters and referents." Scandinavian
Journal of Work, Environment & Health 9(6): 505-10.
• Loubieres, Y., A. de Lassence, et al. (1999). "Acute, fatal, oral
chromic acid poisoning." Journal of Toxicology - Clinical Toxicology
37(3): 333-6.
• Luippold, R. S., K. A. Mundt, et al. (2003). "Lung cancer mortality
among chromate production workers." Occupational & Environmental
Medicine 60(6): 451-7.
• Machle, W. and F. Gregorius (1948). "Cancer of the respiratory
system in the United States chromate-producing industry." Public
Health Rep 63: 114-127.
• MacKie, R. M. (1981). "Clinical dermatology." New York, Toronto:
Oxford University Press.
• Mancuso, R. F. (1951). "Occupational cancer and other health hazards
in a chromate plant: a medical appraisal. II. Clinical and toxicologic
aspects." Industrial Medicine & Surgery 20(9): 393-407.
• Mancuso, T. F. (1975). "Consideration of chromium as an industrial
carcinogen." In: Hutchinson TC, ed. Preceedings of the international
conference on heavy metals in the environment. Toronto, Canada:
Toronto Institute for Environmental Studies, : pp 343-356.
• Medeiros, M. G., A. S. Rodrigues, et al. (2003). "Elevated levels of
DNA-protein crosslinks and micronuclei in peripheral lymphocytes of
tannery workers exposed to trivalent chromium." Mutagenesis 18(1):
19-24.
• Meditext - Medical Management (2005). "Chromium Hexavalent
Salts." TOMES Information System. Denver, CO: Micromedex, Inc.
• Meert, K. L., J. Ellis, et al. (1994). "Acute ammonium dichromate
poisoning." Annals of Emergency Medicine 24(4): 748-50.
• Mertz, W. (1969). "Chromium occurrence and function in biological
systems." Physiological Reviews 49(2): 163-239.
• Mertz, W. (1993). "Chromium in human nutrition: a review." J.
Page 65 of 67
Nutr(123): 626-633.
• Michie, C. A., M. Hayhurst, et al. (1991). "Poisoning with a traditional
remedy containing potassium dichromate." Human & Experimental
• Moller, D. R., S. M. Brooks, et al. (1986). "Delayed anaphylactoid
reaction in a worker exposed to chromium." Journal of Allergy &
Clinical Immunology 77(3): 451-6.
• NIOSH (2005). "Online pocket guide to chemical hazards.
Septemvber 2005." http://www.cdc.gov/niosh/npg/nengapdx.html#c.
• Norseth, T. (1981). "The carcinogenicity of chromium." Environmental
Health Perspectives 40: 121-30.
• Novey, H. S., M. Habib, et al. (1983). "Asthma and IgE antibodies
induced by chromium and nickel salts." Journal of Allergy & Clinical
Immunology 72(4): 407-12.
• OSHA (2006). "OSHA Issues Final Standard on Hexavalent
Chromium." National News Release: 06-342-NAT(February 27, 2006).
• Park, R. M., J. F. Bena, et al. (2004). "Hexavalent chromium and lung
cancer in the chromate industry: a quantitative risk assessment." Risk
Analysis 24(5): 1099-108.
• Pascale, L. R., S. S. Waldstein, et al. (1952). Chromium intoxication,
with special reference to hepatic injury, Journal of the American
Medical Association. 149(15):1385-9, 1952 Aug 9.
• Petrilli, F. L., G. A. Rossi, et al. (1986). "Metabolic reduction of
chromium by alveolar macrophages and its relationships to cigarette
smoke." Journal of Clinical Investigation 77(6): 1917-24.
• PHS (1953). "Health of workers in chromate producing industry: A
study." Washington, DC: U.S. Public Health Service. Publication
no.192.
• Polak, L. (1983). "Immunology of chromium. In: Chromium:
metabolism and toxicity." Burrows, D, ed. Boca Raton, FL: CRC
Press,: pp. 51-135.
• Polak, L., J. L. Turk, et al. (1973). "Studies on contact
hypersensitivity to chromium compounds." Progress in Allergy 17:
145-226.
• Rom, W. N. (2007). "Environmental and Occupational Medicine. 4th
Ed. 2007 by Lippincott Williams & Wilkins."
• Samitz, M. H. (1970). "Ascorbic acid in the prevention and treatment
of toxic effects from chromates." Acta Dermato-Venereologica 50(1):
59-64.
• Saryan, L. A. and M. Reedy (1988). "Chromium determinations in a
case of chromic acid ingestion." Journal of Analytical Toxicology
12(3): 162-4.
• Schaffer, A. W., A. Pilger, et al. (1999). "Increased blood cobalt and
chromium after total hip replacement." Journal of Toxicology - Clinical
• Schiffl, H., P. Weidmann, et al. (1982). "Dialysis treatment of acute
chromium intoxication and comparative efficacy of peritoneal versus
hemodialysis in chromium removal." Mineral & Electrolyte Metabolism
7(1): 28-35.
• Sharma, B. K., P. C. Singhal, et al. (1978). "Intravascular haemolysis
and acute renal failure following potassium dichromate poisoning."
Postgraduate Medical Journal 54(632): 414-5.
• Sheffet, A., I. Thind, et al. (1982). "Cancer mortality in a pigment
Page 66 of 67
plant utilizing lead and zinc chromates." Archives of Environmental

Health 37(1): 44-52.
• Sluis-Cremer, G. and R. du Toit (1968). "Pneumoconiosis in chromite
miners in South Africa." Br J Ind Med 25: 63-67.
• Snyder, C. A., I. Udasin, et al. (1996). "Reduced IL-6 levels among
individuals in Hudson County, New Jersey, an area contaminated with
chromium." Archives of Environmental Health 51(1): 26-8.
• Spruit, D., F. C. van Neer, et al. (1966). "Penetration rate of Cr (3)
and Cr (VI)." Dermatologica 132(2): 179-82.
• Stift, A., J. Friedl, et al. (2000). "Successful treatment of a patient
suffering from severe acute potassium dichromate poisoning with liver
transplantation." Transplantation 69(11): 2454-5.
• Suzuki, Y. (1987). "Anion-exchange high-performance liquid
chromatography of water-soluble chromium (VI) and chromium (III)
complexes in biological materials." Journal of Chromatography A
415(2): 317-24.
• Suzuki, Y. and K. Fukuda (1990). "Reduction of hexavalent chromium
by ascorbic acid and glutathione with special reference to the rat
lung." Archives of Toxicology 64(3): 169-76.
• U.S. Environmental Protection Agency (1998). "Toxicological Review
of Hexavalent Chromium.
• ." National Center for Environmental Assessment, Office of
Research and Development, Washington, DC.
• U.S. Environmental Protection Agency (1998). "Toxicological Review
of Trivalent Chromium.
• ." National Center for Environmental Assessment, Office of Research
and Development, Washington, DC.
• U.S. Environmental Protection Agency (2002). "Common Chemicals
Found at Superfund Sites." Available at:
http://www.epa.gov/superfund/resources/chemicals.htm.
• van Heerden, P. V., I. R. Jenkins, et al. (1994). "Death by tanning--a
case of fatal basic chromium sulphate poisoning." Intensive Care
Medicine 20(2): 145-7.
• Wiegand, H. J., H. Ottenwalder, et al. (1984). "Disposition of
intratracheally administered chromium(III) and chromium(VI) in
rabbits." Toxicology Letters 22(2): 273-6.
• World Health Organization (1990). "Chromium (Environmental Health
Criteria 61) International Programme on Chemical Safety,." Geneva,
Switzerland.
• World Health Organization (1990). "Chromium (Environmental Health
Criteria 61) International Programme on Chemical Safety,." Geneva,
Switzerlands.
• Zhitkovich, A., Y. Song, et al. (2001). "Non-oxidative mechanisms are
responsible for the induction of mutagenesis by reduction of Cr(VI)
with cysteine: role of ternary DNA adducts in Cr(III)-dependent
mutagenesis." Biochemistry 40(2): 549-60.
Page 67 of 67

WWW - Atsdr.cdc - Gov/csem/ Downloadable PDF

Uploaded by

Copyright:

Available Formats

WWW - Atsdr.cdc - Gov/csem/ Downloadable PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

WWW - Atsdr.cdc - Gov/csem/ Downloadable PDF

Uploaded by

Copyright:

Available Formats

Agency for Toxic Substances and Disease Registry

Case Studies in Environmental Medicine (CSEM)

How to Use This Course ...................................................................................................3

CDC/ATSDR Author(s): Dianyi Yu, M.D.

CDC/ATSDR Planners: Charlton Coles, Ph.D.; John Doyle, MPA; Bruce

Peer Reviewers: Jonathan Borak, MD, DABT; Dave Hewitt, MD.

U.S. Department of Health and Human Services

How to Use This Course

• The HTML version www.atsdr.cdc.gov/csem/chromium/ provides

The HTML version offers interactive exercises and prescriptive feedback to

• Take the Initial Check to assess your current knowledge about

Exposure • Identify sources of chromium exposure.

Who is at Risk • Identify who is at risk of exposure to chromium.

Clinical • Describe characteristic clinical presentations of patients with acute or

With the exception of the complaints mentioned, review of systems is

The patient has been employed as a mathematics teacher for 13 years; he

Physical examination reveals an alert white male with 10 erythematous

Initial laboratory findings include evidence of 2+ proteinuria and hematuria,

aminotransferase (ALT); known as serum glutamic-pyruvic transaminase

2. Information suggesting an environmental etiology includes the following:

when he visited Chicago. Proximity of the patient’s home to an industrial

4. If effluent from the plant has reached the groundwater, community

5. The most important pathways for possible chromium exposure in this

6. Cr(VI) is a powerful oxidizing agent. In the plasma and cells, it is readily

7. Yes. Persistent dermal ulcers, respiratory tract irritation, and pulmonary

8. The potential risk of chromium-induced respiratory system cancer from

9. If exposure was recent, chromium levels in blood or urine may be used to

This patient’s case might be a sentinel for community exposure. You

Learning Upon completion of this section, you will be able to

Definition Chromium is a hard steel-gray metal that is highly resistant to oxidation,

These industries are the most important industrial sources of chromium in

In the metallurgical industry, chromium is an important component of

In the chemical industry, chromium is used

Refractory uses of chromium include magnesite-chrome firebrick for

Different Chromium exists in a series of oxidation states from -2 to +6 valence. The

Chromium in chromite ore is in the trivalent state; industrial processes also

Other significant sources of Cr(III) are mineral supplements, brewer’s yeast,

The biologically active form of an organic Cr(III) complex, often referred to

Progress Check 1. Which of the following statements is correct?

A. Chromium is highly resistant to reduction.

To review relevant content, see “Essential Dietary Nutrient” in this

Answers 1. The correct answer is B. Cr(III) is an essential dietary mineral in

Where Is Chromium Found?

Learning Upon completion of this section, you will be able to

Introduction Naturally occurring chromium is usually present as trivalent Cr(III).

Coal and oil combustion contribute an estimated 1,723 metric tons of

Electroplating, leather tanning, and textile industries release relatively large

A survey conducted from 1974 to 1975 provides estimates of chromium

Chromium waste slag containing potentially hazardous levels of Cr(VI)

Community exposure from this fill occurred in a variety of ways. Wind

The general population is exposed to chromium by eating food or food

Summary of Environmental and Occupational Sources of Chromium Exposure

Environmental Environmental sources of chromium include

Occupational Occupational sources of chromium include

Key Points • Chromium is released to air primarily by combustion processes and

Progress Check 2. What sources does chromium contamination result from?

A. Stationary fuel combustion (residential, commercial, and industrial).

To review relevant content, see “Air Contamination,” “Water

What Are the Routes of Exposure for Chromium?